‘Totally Underrepresented’: The Push to Put Men’s Health on the Global Agenda 01/06/2026 Stefan Anderson Launch event of the Global Action on Men’s Health report underway on the sidelines of the World Health Assembly in Geneva. GENEVA – The 79th World Health Assembly closed last Saturday after a long week of negotiations over the globe’s most pressing health crises: financing gaps, rare diseases, a workforce shortage counted in the millions, a string of wars and humanitarian emergencies, and dozens of other resolutions. Yet one policy area affecting half of the global population – men’s health – was, as almost every year, nowhere to be found on the agenda. For an assembly built to tackle the deepest global inequalities, crossed with the intense competition for funds across all global health policy areas amidst what the WHO calls a “global health financing emergency”, the case for prioritising the world’s dominant sex is far from an easy sell. Its counterpart, women’s health, remains badly underfunded and under-researched. Only 6% of private healthcare capital goes to research on conditions affecting women, 0.5% of all neuroscience research conducted since the invention of MRI in the 1990s considers factors specific to women, and fewer than 5% of clinical trials report sex-disaggregated data. Women are also diagnosed later than men for more than 700 diseases, while spending 25% more of their lives in poor health than men. “Most medical research has been on men’s bodies at the expense of women, so it is absolutely true that women’s medical research is underfunded,” Peter Baker, the chief executive of Global Action on Men’s Health (GAMH), who has worked in the men’s health space for nearly 50 years, told Health Policy Watch. But that doesn’t mean men’s health is always well understood, Baker said. Nor, he argued, should a focus on men’s health entail less attention on the women’s health crisis. “What the focus hasn’t been on is how to stop men getting ill,” he said. “We don’t know enough about how to prevent health problems in men, and that includes early diagnosis, getting men to use services sooner.” “We don’t want men’s health to improve at the expense of women’s health,” Baker said. “We want the health of everyone to improve.” ‘Predestined to die young’ The numbers underpinning Baker’s case were highlighted in a new GAMH report launched launched at a WHA side event in Geneva, organized in collaboration with the Global Self-Care Federation.Male life expectancy globally is 71.5 years, five years shorter than women’s. There is no country in the world where men live longer than women.Men also face a higher burden than women across most of the top 20 causes of premature death, including cardiovascular disease, liver disease, and road traffic accidents, the report found.Suicide rates hold perhaps the most tragic inequality: three in every four people who end their own lives globally are men.”There’s a view that men are biologically predestined to die young, that we can’t do much about it, because it’s basically biological, which is completely untrue,” Baker said. “There’s a small biological element to men’s poor health, but it’s not the biggest factor at all.””Men aren’t some kind of distant, weird race,” he said. “Men are people’s fathers, their brothers, their sons. Most of us care about the men in our lives, want them to be healthy.” A push to get men’s health into policy The launch, held in a 14th floor boardroom with view of Mont Blanc towering in the backround, did not aim to attact a large crowd. But it set out a sprawling agenda, outlining six priorities at the intersection of men’s health and self-care. Those include: embedding men in health policy, strengthening regulation of health risks, improving access to male-responsive services, building health literacy, training the workforce, and accelerating research. The report argues self-care should be treated as a valuable health care intervention, integrated into national policies and health strategies, rather than purely a matter of individual responsibility. Yet its authors are careful to stress that self-care must be viewed as comlpimentary to national health systems, pharmacy, and other central components of health infrastructure. “Men have not figured in health policy in most countries and globally,” Baker told the Geneva meeting. Even the WHO’s own guideline on self-care interventions for health and well-being — a reference document for member states — mentions men 37 times. The equivalent words for women appear 170 times. Men are referenced only in the context of HIV and condom use. Mental health, infertility, male cancers, sexual dysfunctions and cardiovascular disease are absent. “Men are totally under-represented in health policy,” Baker said. “So the key driver of change is not actually being addressed.” Men are much less likely than women to consume fruit and vegetables, more likely to drink alcohol heavily — 52% of men globally versus 36% of women — and five times more likely to use tobacco by 2030 on current trends. This puts them at significantly higher risks for liver diseases, lung cancers and respiratory illnesses, among other NCDs, Men also are 60% less likely than women to recognise the potential significance of a change in a mole, a basic indicator of skin cancer awareness. They also make up the overwhelming majority of the world’s smoking population. Of the world’s 1.2 billion tobacco users, more than a billion are male. In the Eastern Mediterranean region, men account for 94% of tobacco users, and 91% in parts of Asia. Yet the reticence of governments to prioritise men’s health, Baker explained, is not a strict left or right issue – but a push and pull from opposite directions of the political spectrum all at once. “Governments of the left tend to the view that women’s health is the priority, because women are the disadvantaged sex,” he said. “That if you throw resources at men, you’re taking resources away from women, and men don’t deserve special treatment because they are the privileged and powerful sex.” “Governments on the right, on the other hand, don’t want to invest in men’s health because they see the male role to be powerful and dominant, and they don’t want to do anything which changes that,” Baker added. “That giving attention to men’s health makes men look like they’re weak when they should be strong.” The economics of care for all Close to $380 billion in losses could have been avoided across just six-high income countries – Australia, Canada, Germany, Japan, the UK and the US – in 2023 if the five leading causes of preventable premature male deaths were avoided, according to an assessment by GAMH and the men’s health advocacy group Movember, published earlier this year. Those six countries account for roughly 350 million men, or just under one-tenth of the world’s male population. The other 90% of men on the planet, including all those living in low-and middle-income countries – where health outcomes fare worse due to thinner preventive care infrastructure – are not included in the study’s scope at all, paiting a stark picture of what the true costs of overlooking men’s health may add up to globally. Patricia Pascual, global head of public affairs at Opella, the consumer-health company that supported the report, said the universal-health-coverage agenda makes the case obvious. “Universal health care coverage cannot be just about limiting [services] to people who are sick,” she told the panel. “Especially for men, as we know behaviourally, we need to get them into the system much earlier.” The economic case for closing the women’s health gap completes the economic argument for universal healthcare enshrined in the WHO’s Constitution. Addressing women’s poor health outcomes could add around $1 trillion to global GDP annually by 2040, according to the latest World Economic Forum assessment released last week. The economic case for closing the women’s health completed the economic argument for universal health care enshrined in the WHO charter. Addressing women’s poorer health outcomes could add around $1 trillion to global GDP annually by 2040, according to World Economic Forum calculations. Women, Pascual added, are still the de facto health managers of most families. “In many households, women are still the CEOs of healthcare within their families. So when men delay care, the burden does not disappear. It just gets handed over. It shifts to families, caregivers and partners.” “Investing in men’s health is not competing with women’s health,” she added. “It actually strengthens it.” Baker argues the numbers baking up action on men and women’s health as a joint cause should be the guiding line towards universal health care. But barriers are still hard to surmount. “There’s another view … that because we live in a patriarchy where men are generally more privileged and powerful, the fact that they have poor health is kind of the price that men have to pay for being the dominant sex,” Baker explained. “I think also in circles where gender and health are discussed, often gender is seen as being about women’s health only.” “That’s probably one of the biggest barriers [to progress],” Baker said. The manosphere ‘self-help’ problem As advocates in Geneva attempt to push men’s health higher up the agenda of WHO and its executive assembly, a parallel ecosystem of online influences is stepping into the void left by national governments and international organisations. This new world of men’s influencers, known in popular discourse as “The Manosphere”, receives engagement from millions of young men across every continent every week. Their content positions itself as a tool for “self-care”. But their world is far detached from the mission of delegates at the Geneva meeting. It has skyrocketed into global popular culture, featuring as a key subject of multi-Emmy and Golden Globe-winning show Adolescence – which Baker noted helped push the men’s health conversation forward in the UK – to making the title of British documentarian Louis Theroux’s recent chart-topping Netflix special, Inside the Manosphere. The constellation of men’s influencers is vast. From mainstream ‘alpha-male’ figures like Andrew Tate, a convicted sex trafficker in Romania and current fugitive from 21 rape charges in the United Kingdom, who broadly argues the value of men is defined by bank accounts, women and physical superiority, to a new generation led by “looksmaxxers” such as Clavicular, a 20-year old internet phenomenon who advocates improving men’s looks by taking methamphetamine, unregulated peptides, testosterone, and hitting your own face with a hammer to change facial bone structure. Beyond questionable health advice, the figures in the Manosphere frequently cross over into the world’s of racism, anti-semitism, and deep misogyny. Clavicular and Tate were recorded earlier this year in a party bus chanting “We would definitely want to keep them at arm’s length, because we don’t want to associate ourselves with organisations that are misogynistic or anti-feminist,” Baker said. The often extreme political and social views of the influencers across the Manosphere has not stopped millions of digitally connected young men from taking their “self-care” and self-image advice seriously. A survey of more than 3,000 young men aged 16 to 25 across the UK, UK and Australian found that 63% regularly watch “men and masculinity” influencers, according to the Movember Institute, which conducted the research. Young men who regularly consumed masculinity influencer content were more likely to report worse mental health, less willingness to prioritise or treat mental health, and took steroids at higher rates, the survey found. Of those, 27% reported feelings of “worthlessness” – and indicator Baker says point to increasing body dysmorphia amount young men. “On the surface it looks like it’s about fitness and looking after yourself, and there’s obviously nothing wrong with being fit and healthy,” Baker said, alluding to the fact that many men enter the masculinity influencer world through fitness content. “But it’s reifying a pretty unrealistic view of what a man has to be physically. It fuels body image dysmorphia.” “We’re seeing many more cases of young men having body image dysmorphia, exercise addiction, problematic relationship with food, using steroids,” Baker said. “We’re also seeing an increase in men using dodgy hair-loss drugs. It just promotes such anxiety around how men look.” “Women have suffered with that anxiety for many years, and the manosphere is pushing men in a similar direction.” A turning point, maybe Baker has been in this field for nearly four decades. He started writing about masculinity in the British pro-feminist men’s groups of the 1980s, became a journalist, then chief executive of the UK Men’s Health Forum in 2000, when a Tony Blair-era policy focus on health inequalities briefly opened the funding tap. The 2010 financial crisis closed it. For most of the decade that followed, men’s health drifted from the policy conversation, sustained by a small network of advocates and a slow accumulation of evidence rather than political momentum. “We’ve had a lot of false dawns,” Baker told the Geneva meeting. “But I think now we really are at a bit of a turning point.” But momentum – this time – seems to be gathering at the highest level. Nine currently have national men’s health policies: Australia, Brazil, England, Iran, Ireland, Malaysia, Mongolia, the Philippines and South Africa. Ireland was first, in 2008-09, and is now on its third action plan. Biddy O’Neill, national policy lead for men’s health at Ireland’s Department of Health, told the Geneva meeting that policy is the precondition for everything else. “Policy provides the mandate,” she said. “The political will follows after men’s health is identified as a priority.” Getting there required unusual amounts of legwork. O’Neill described how her team toured the country during the initial consultation, deliberately seeking out men least likely to attent a formal event in a government building. “We went around the country almost in a bus to engage with men, different groups of men,” she said. “We targeted specific focus groups with lower-disadvantaged groups, men who didn’t want to come to bigger events. That was really important.” Resistance came from within the government too. “Other government departments did not see they had anything to do with men’s health,” O’Neill said. The inequalities the original policy was trying to address ran along familiar lines. “Poorer men, their life expectancy continues to be really lagging.” Lower-income men are more likely to drink heavily, smoke, take their own lives and die early of cardiovascular disease, O’Neill said. Ireland was the first country in the world to introduce a 100% indoor smoking ban, in 2004. Seventy-nine countries have followed, O’Neill noted. But the case Baker returned to in his conclusion to is the simplest one: treating men’s health as a public health issue does not require treating it as a zero-sum competition with anyone else’s. “We don’t have to think in terms of binary choices. It’s not either or.” The numbers underpinning Baker’s case were highlighted in a new GAMH report launched at a World Health Assembly side event in Geneva, organised in collaboration with the Global Self-Care Federation. Male life expectancy globally is 71.5 years, five years shorter than women’s. There is no country in the world where men live longer than women. Men also face a higher burden than women across most of the top 20 causes of premature death, including cardiovascular disease, liver disease, and road traffic accidents, the report found. Suicide rates hold perhaps the most tragic inequality: three in every four people who end their own lives globally are men. “There’s a view that men are biologically predestined to die young, that we can’t do much about it, because it’s basically biological, which is completely untrue,” Baker said. “There’s a small biological element to men’s poor health, but it’s not the biggest factor at all.” Total alcohol consumption per capita (age 15 years or older), WHO regions and global, 2000-2019. Men are much less likely than women to consume fruit and vegetables, more likely to drink alcohol heavily — 52% of men globally versus 36% of women — and five times more likely to use tobacco by 2030 on current trends. Men also are 60% less likely than women to recognise the potential significance of a change in a mole, a basic indicator of skin cancer awareness. They also make up over one billion of the world’s 1.2 billion smokers. In some regions, including the Eastern Mediterranean and parts of Asia, over 90% of smokers are men. The combined health effects resulting from this list of potentially deadly habits put men at significantly higher risks for liver diseases, lung cancers and respiratory illnesses, among other NCDs. “Men aren’t some kind of distant, weird race,” he said. “Men are people’s fathers, their brothers, their sons. Most of us care about the men in our lives, want them to be healthy.” A new report, and a push for policy The new Global Action on Men’s Health report was released on the sidelines of the WHO’s World Health Assembly in Geneva. The launch, held in a 14th-floor boardroom with a view of Mont Blanc towering in the background, did not aim to attract a large crowd. But it set out a sprawling agenda, outlining six priorities at the intersection of men’s health and self-care. Those include: embedding men in health policy, strengthening regulation of health risks, improving access to male-responsive services, building health literacy, training the workforce, and accelerating research. The report argues self-care should be treated as a valuable health care intervention, integrated into national policies and health strategies, rather than purely a matter of individual responsibility. Yet its authors are careful to stress that self-care must be viewed as complementary to national health systems, pharmacy, and other central components of health infrastructure. “Men have not figured in health policy in most countries and globally,” Baker told the Geneva meeting. “They are totally under-represented in health policy, so the key driver of change is not actually being addressed.” Even the WHO’s own guideline on self-care interventions for health and well-being — a reference document for member states — mentions men 37 times. The equivalent words for women appear 170 times. Men are referenced only in the context of HIV and condom use. Mental health, infertility, male cancers, sexual dysfunctions and cardiovascular disease are absent. Yet the reticence of governments to prioritise men’s health, Baker explained, is not a strict left or right issue – but a push and pull from opposite directions of the political spectrum all at once. “Governments of the left tend to the view that women’s health is the priority, because women are the disadvantaged sex,” he said. “That if you throw resources at men, you’re taking resources away from women, and men don’t deserve special treatment because they are the privileged and powerful sex.” “Governments on the right, on the other hand, don’t want to invest in men’s health because they see the male role to be powerful and dominant, and they don’t want to do anything which changes that,” Baker added. “That giving attention to men’s health makes men look like they’re weak when they should be strong.” The economics of care for all Table from the joint GAMH and Movember report on the costs of inaction on men’s health. Close to $380 billion in direct economic losses could have been avoided across just six high-income countries – Australia, Canada, Germany, Japan, the UK and the US – in 2023 if the five leading causes of preventable premature male deaths were avoided, according to an assessment by GAMH and the men’s health advocacy group Movember, published earlier this year. Those six countries account for roughly 350 million men, or just under one-tenth of the world’s male population. The other 90% of men on the planet, including all those living in low-and middle-income countries – where health outcomes fare worse due to thinner preventive care infrastructure – are not included in the study’s scope at all, painting a stark picture of what the true costs of overlooking men’s health may add up to globally. Addressing women’s poor health outcomes could add another $1 trillion to global GDP annually by 2040, according to the latest World Economic Forum calculations released last week. Patricia Pascual, global head of public affairs at Opella, the consumer-health company that supported the report, said the economics of the universal health coverage agenda make the case for closing both care gaps obvious. “Universal health care coverage cannot be just about limiting [services] to people who are sick,” she told the panel. “Especially for men, as we know behaviourally, we need to get them into the system much earlier.” The woman’s health gap in numbers, according to World Economic Forum research. Women, Pascual added, are still the de facto health managers of most families. “In many households, women are still the CEOs of healthcare within their families. So when men delay care, the burden does not disappear. It just gets handed over. It shifts to families, caregivers and partners.” “Investing in men’s health is not competing with women’s health,” she added. “It actually strengthens it.” Baker argues that the numbers baking up action on men’s and women’s health as a joint cause should be the guiding line towards universal health care. But barriers are still hard to surmount. “There’s another view … that because we live in a patriarchy where men are generally more privileged and powerful, the fact that they have poor health is kind of the price that men have to pay for being the dominant sex,” Baker explained. “I think also in circles where gender and health are discussed, often gender is seen as being about women’s health only.” “That’s probably one of the biggest barriers [to progress],” Baker said. The manosphere ‘self-help’ problem Masculinity influencers have come to dominate reach in the online self-help space, particularly for young men. As advocates in Geneva attempt to push men’s health higher up the agenda of WHO and its executive assembly, a parallel ecosystem of online influencers is stepping into the void left by national governments and international organisations. This new world of men’s influencers, known in popular discourse as “The Manosphere”, receives engagement from millions of young men across every continent every week. Their content positions itself as a tool for “self-care”. But their world is far detached from the mission of delegates at the Geneva meeting. It has skyrocketed into global popular culture, featuring as a key subject of multi-Emmy and Golden Globe-winning show Adolescence – which Baker noted helped push the men’s health conversation forward in the UK – to featuring in the title of British documentarian Louis Theroux’s recent chart-topping Netflix special, Inside the Manosphere. The constellation of men’s influencers is vast. From mainstream ‘alpha-male’ figures like Andrew Tate, a convicted sex trafficker in Romania and current fugitive from 21 rape charges in the United Kingdom, who broadly argues the value of men is defined by bank accounts, women and physical superiority, to a new generation led by “looksmaxxers” such as Clavicular, a 20-year old internet phenomenon who advocates improving men’s looks by taking methamphetamine, unregulated peptides, testosterone, and hitting your own face with a hammer to change facial bone structure. Beyond questionable health advice, the figures in the Manosphere frequently cross over into the worlds of racism, anti-semitism, and deep misogyny. Clavicular and Tate were recorded together earlier this year in a party bus in Miami, chanting the lyrics to a notorious Kanye West song titled ‘Heil Hitler’. “We would definitely want to keep them at arm’s length, because we don’t want to associate ourselves with organisations that are misogynistic or anti-feminist,” Baker said. Percentage of young men from the Movember survey who regularly consume masculinity influencer content, by country. The often extreme political and social views of the influencers across the Manosphere have not stopped millions of digitally connected young men from taking their “self-care” and self-image advice seriously. A survey of more than 3,000 young men aged 16 to 25 across the US, UK and Australia, found that 63% regularly watch “men and masculinity” influencers, according to the Movember Institute, which conducted the research. Young men who regularly consumed masculinity influencer content were more likely to report worse mental health, less willingness to prioritise or treat mental health, and take steroids at higher rates, the survey found. Of those, 27% reported feelings of “worthlessness” – an indicator Baker says points to increasing body dysmorphia among young men. “On the surface, it looks like it’s about fitness and looking after yourself, and there’s obviously nothing wrong with being fit and healthy,” Baker said, alluding to the fact that many men enter the masculinity influencer world through fitness content. “But it’s reifying a pretty unrealistic view of what a man has to be physically. It fuels body image dysmorphia.” “We’re seeing many more cases of young men having body image dysmorphia, exercise addiction, problematic relationships with food, using steroids,” Baker said. “We’re also seeing an increase in men using dodgy hair-loss drugs. It just promotes such anxiety around how men look.” “Women have suffered with that anxiety for many years, and the manosphere is pushing men in a similar direction.” A turning point, maybe Ireland was the first country in the world to adopt a national-level men’s health policy. Baker has been in this field for nearly five decades. He started writing about masculinity in the British pro-feminist men’s groups of the 1980s, became a journalist, and then chief executive of the UK Men’s Health Forum in 2000, when a Tony Blair-era policy focus on health inequalities briefly opened the funding tap. The 2010 financial crisis closed it. For most of the decade that followed, men’s health drifted from the policy conversation, sustained by a small network of advocates and a slow accumulation of evidence rather than political momentum. “We’ve had a lot of false dawns,” Baker said. “But I think now we really are at a bit of a turning point.” Nine countries currently have national men’s health policies: Australia, Brazil, England, Iran, Ireland, Malaysia, Mongolia, the Philippines and South Africa. Canada is expected to publish its first by the end of 2026, which would make it the tenth and the first G7 country other than the UK to have one. Ireland was first, in 2008-09, and is now on its third action plan. Biddy O’Neill, national policy lead for men’s health at Ireland’s Department of Health, told the Geneva meeting that policy is the precondition for everything else. “Policy provides the mandate,” she said. “The political will follows after men’s health is identified as a priority.” Getting there required unusual amounts of legwork. O’Neill described how her team toured the country during the initial consultation, deliberately seeking out men least likely to attend a formal event in a government building. “We went around the country almost in a bus to engage with men, different groups of men,” she said. “We targeted specific focus groups with lower-disadvantaged groups, men who didn’t want to come to bigger events. That was really important.” Resistance came from within the government, too. “Other government departments did not see they had anything to do with men’s health,” O’Neill said. The inequalities the original policy was trying to address ran along familiar lines. “Poorer men, their life expectancy continues to be really lagging”, she added, noting lower-income men are more likely to drink heavily, smoke, take their own lives and die early of cardiovascular disease. But the case Baker returned to in his conclusion is a simple one: treating men’s health as a public health issue does not require treating it as a zero-sum competition with anyone else’s. “We don’t have to think in terms of binary choices. It’s not either or.” Congo Ebola Outbreak Now Third-Largest on Record as Suspected Cases Pass 1,000 01/06/2026 Stefan Anderson Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. A rare and deadly strain of the Ebola virus is spreading rapidly through a region of the Democratic Republic of the Congo (DRC) that has never previously experienced the disease, pushing suspected cases past 1,000 this week amid severe logistical hurdles and mounting community resistance. The outbreak, caused by the Bundibugyo version of the virus, has claimed at least 246 lives in the DRC since it first emerged in early May. Three Red Cross volunteers are among the dead after contracting the virus while managing the bodies of Ebola victims without adequate protective gear before the outbreak was detected. The Ministry of Health in the DRC described the outbreak in a joint statement with the World Health Organization (WHO) late Sunday as “a rapidly evolving situation, with cases and deaths notified in several health zones” across Ituri, North Kivu and South Kivu. “Persistent challenges include early detection and isolation of cases, contact tracing, safe and dignified burials, robust infection prevention and control in health facilities, and strong community awareness,” the ministry added. Medical charity Médecins Sans Frontières warned that the true scale of the crisis remains unknown, calling the situation “deeply alarming.” “The reality today is that nobody knows the true scale and severity of this outbreak. New suspected cases are being reported daily, yet hundreds of samples remain untested,” said Dr Alan Gonzalez, deputy director of MSF. “Never before has an Ebola outbreak recorded so many cases so soon after its declaration.” The crisis currently ranks as the third-largest Ebola outbreak on record based on confirmed and suspected cases, and the virus has already crossed borders, with neighboring Uganda reporting nine confirmed cases and one death. WHO Director-General Dr Tedros Adhanom Ghebreyesus traveled to Bunia, the epicenter of the outbreak, to oversee the international response on the ground. “I wish the circumstances were different, but I came because the people of Ituri, the Kivus, and all of DRC deserve to know they are not alone,” Tedros said. Prior to arriving in Bunia, Tedros met with Prime Minister Judith Suminwa Tuluka in Kinshasa to coordinate the government-led response. He is scheduled to hold subsequent meetings with local ministers, the provincial governor, the Congolese Red Cross, Africa CDC, UNICEF and the World Food Programme. “DRC has faced Ebola before, sixteen times, and has ended every outbreak,” Tedros said. “This is the seventeenth. That history gives me real confidence.” ‘Not here to tell people what to do’ The recent Ebola outbreak serves as a grim reminder that nature does not wait for treaty negotiations. The outbreak is centered in Ituri Province, a region already beset by food insecurity and clashes between armed groups. While eastern DRC cities just five to seven hours away have battled the virus before, Ituri has no history of the disease. Because residents lack the instincts and training to identify or manage the illness, the sudden arrival of international medical personnel enforcing strict infection protocols has sparked a mixed and sometimes hostile local response. Much of this mistrust stems from the grim reality of Ebola containment, which requires isolating the sick and strictly prohibiting families from interacting with their deceased loved ones due to the danger of infection. The bodies of Ebola victims remain highly infectious after death. Traditional funeral rites in the region, during which mourners touch and wash the deceased, have been a persistent driver of transmission in past outbreaks. While health guidelines mandate that trained teams conduct these “safe and dignified” burials, convincing the local population to set aside their deeply held rituals and hand over their loved ones to foreigners in protective suits has proven incredibly difficult. Distribution of suspected and confirmed cases of Bundibugyo virus disease in Democratic Republic of the Congo and Uganda, as of 29 May 2026. Tedros addressed this gulf between community sentiment and the harsh necessity of the outbreak response, acknowledging the cultural friction surrounding the handling of the dead. “Safe, dignified burials matter too. I understand how painful it is to lose someone, and how much it means to honour them properly,” Tedros said. “But certain practices, including touching the bodies of those who have died from Ebola, can spread the virus further. While we grieve for those we have lost, we must do everything we can so that we do not lose another.” He added that the World Health Organization’s goal is to act as a partner, rather than an enforcer, in the region. “We are not here to tell people what to do. We are here to listen,” he said. “Communities understand their own challenges and their own solutions. Our role is to support you in implementing those solutions, together. Community ownership is what will bring this outbreak to an end. “ Doctors in the DRC reported three attacks on health facilities treating Ebola patients in Ituri over the weekend. The violence is largely driven by civilians angry over not being able to bury dead family members, alongside a smaller faction, estimated at about one in four by The Lancet, who believe the outbreak is a hoax. The hostility echoes the severe violence directed at health workers during the 2018-2020 Ebola outbreak in neighboring North Kivu, where armed attacks on treatment centers repeatedly forced medical teams to suspend operations and resulted in multiple fatalities among responders. What happened? Number of confirmed cases (n=125) and deaths (n=17) by date of reporting in the Democratic Republic of the Congo as of 27 May 2026. Unlike the more commonly known Ebola and Sudan viruses, there is no approved vaccine or preventive treatment for the Bundibugyo strain, forcing medical teams to focus entirely on managing patient symptoms and treating other underlying diseases. Confirming a diagnosis requires special test kits specific to the individual virus strain, largely because Ebola shares early symptoms with other illnesses endemic to eastern DRC, such as malaria and typhoid. However, kits for the Bundibugyo virus are currently in short supply, significantly slowing case confirmation and subsequently delaying contact tracing and patient isolation. “This outbreak is unfolding in a context where medical needs are already acute, and we are now at real risk of a silent escalation of other critical health problems people face every day,” Gonzalez said. “So many health facilities are overwhelmed, and access to regular, non-Ebola care is affected while many people remain at home, too afraid to seek care.” The African Union estimates that approximately $264 million will be required for response operations in the DRC and Uganda to contain the virus, with an additional $54 million needed to strengthen preparedness across neighboring high-risk countries, including South Sudan. Officials caution the figures are preliminary and could increase as the outbreak progresses. Tedros emphasized that the WHO will continue to coordinate closely with the DRC government, stressing that emergency investments made during the current crisis must be leveraged to fortify the country’s health infrastructure for the future, a sentiment the DRC Health Ministry in its joint statement. Support will continue after the outbreak ends and the public health emergency declared by the UN Health agency draws to a close. “Our commitment doesn’t end when an outbreak does,” Tedros said. “We want to leave behind health workers, hospitals, laboratories and services that will serve the people of Ituri for many years to come.” Border shutdown stokes shortage fears 'We saw Ebola patients trying to push though to come into our country'Uganda Permanent Secretary for Health Dr Diana Atwine tells Focus On Africa's Waihiga Mwaura that her country closed the borders with the DRC to try and contain the current Ebola outbreak. pic.twitter.com/dtWv5Nzqjw — BBC News Africa (@BBCAfrica) May 28, 2026 The international response is currently being hindered by critical supply shortages, complex travel restrictions and partial border closures in place between Congo, Uganda and Rwanda. Movement is restricted in and out of the airport in Bunia, an early center of the outbreak, and the city of Goma on the Rwandan border. While most border closures include loopholes to allow humanitarian aid to pass, the reality on the ground is more complex, and aid workers frequently do not know if they will be permitted to cross a frontier until they arrive at a checkpoint. These travel restrictions compound existing logistical challenges in a region characterised by rudimentary road infrastructure and the presence of rebel groups, delaying the arrival of specialist personnel and leaving the delivery of protective equipment, medical supplies and food in doubt. MSF noted from experience that border and airport closures severely hinder outbreak responses and isolate countries that urgently require international support. As suspected case numbers continue to rise, aid staff are increasingly concerned that food, medicines and protective equipment will become more expensive and difficult to source. “You can’t expect a big Ebola response and then not let people out of the province,” Trish Newport, Médecins Sans Frontières’ emergency-program manager told Bloomberg. Image Credits: John Wessels/ MSF, Joël Lumbala/ WHO. Historic WHA Resolution on Fatty Liver Disease Opens Door for Integration into National NCD Strategies 29/05/2026 Sophia Samantaroy Steatotic liver disease, commonly known as fatty liver disease, is linked to the same risk factors that cause other leading NCDs – unhealthy diets, obesity, tobacco use and alcohol misuse. Steatotic liver disease (SLD) was recognized as a “missing piece” of the global noncommunicable disease response in a milestone World Health Assembly resolution last week. With countries making extraordinary progress in combating viral hepatitis, SLD, formerly known as fatty liver disease, is now the fastest-growing chronic liver disease – but far less recognized. Experts and advocates believe the new World Health Asssembly (WHA) decision will trigger more awareness and action in countries and globally. GENEVA– The WHA’s resolution recognizing steatotic liver disease (fatty liver) as an NCD is a long-awaited milestone for a chronic liver condition that carries a huge global health burden but is dramatically under-recognized, experts and patient advocates say. “What we aimed to do is get SLD recognized as a non-communicable disease,” Debbie Shawcross, Secretary General of the European Society for the Study of the Liver (EASL) told Health Policy Watch. “Because we know in these populations, people don’t just suffer from liver disease. They also have cardiovascular disease, chronic kidney disease, diabetes, and more.” Debbie Shawcross, Secretary General, EASL Until very recently, the biggest focus for liver disease was viral hepatitis: “Rightly so, all our resources went into the pandemic of hepatitis C and B.” But now with vaccines for hep B and an antiviral cure for hep C, “we are realizing that what is left behind is a disease that is unaddressed and accelerating.” Shawcross spoke at a high level side event sponsored by EASL last Thursday, the same day that the new resolution was approved by WHA. The event included experts from EASL’s Saudi Arabia affiliate, the NCD Alliance and the Organization of Economic Co-Operation and Development (OECD), as well as Spain’s Director General of Public Health and the Minister of Health from Egypt, which co-sponsored the WHA resolution along with 15 other countries. Egypt: a ‘missing piece’ in the global NCD response Professor Khaled Abdel-Gaffar, Minister of Health, Egypt. The rapid rise in metabolic liver disorders represents the “next great public health challenge,” said Khaled Abdel Ghaffar, Egyptian Minister of Health, at the EASL event. Egypt was one of the first WHO member states to sound the global health alarm around SLD after having grappled years earlier with some of the world’s highest rates of hepatitis C infection – and related viral liver disease burden. What followed was a landmark national campaign to eradicate hep C. But Egypt also suffers from a growing prevalence of diabetes, obesity, and cardiovascular disease – all risk factors for SLD. So early on, it became a champion for recognition of the liver disease as an important NCD. “Building on our experience and recognizing this urgent global need, Egypt has taken another decisive step in leadership,” said Ghaffar. “We proudly sponsored the landmark WHO resolution steatotic liver disease, a missing piece in the global non-communicable disease response.” Growing SLD burden closely linked to diabetes and obesity Comparison of a healthy liver and one with SLD, commonly known as fatty liver disease. SLD affects an estimated 1.7 billion adults globally – who suffer from the metabolic-associated liver dysfunction. In WHO’s European region alone, some 800,000 people die of advanced liver disease each year – costing some $64 billion annually. Its former name, fatty liver disease, remains in fact, an apt description of the condition insofar as SLD is linked to an excess build up of fat in the liver. This may be due to heavy alcohol use or to metabolic dysfunctions related to other NCDs, such as: obesity, insulin resistance, hyperglycemia or pre-diabetes, high cholesterol levels, and hypertension. With few early warning signs, the disease can quickly progress to severe inflammation, cirrhosis, and liver cancer. Globally, the number of new cases of liver cancers have already increased by 50% in the past decade–and are expected to double by 2050. Experts point to SLD as now a major cause of the current surge of liver cancer–which is in turn fueled by rising obesity and diabetes rates. The resolution highlights the shared NCD risk factors characteristic to the development of SLDs, including unhealthy diets, air pollution, smoking, physical inactivity and consequent obesity, as well as harmful alcohol use. It officially incorporates SLD into the broader umbrella of NCDs addressed by the global health agency. Member states are urged to integrate SLD into their noncommunicable disease strategies through strengthened prevention, early detection, primary care services, and public awareness. And the resolution calls on WHO to support research, surveillance, and equitable access to diagnostics and treatment. “For the first time, liver disease receives formal recognition within the global noncommunicable disease agenda,” EASL said in a statement, hailing the resolution as a “turning point” for liver health worldwide. Now, said Shawcross, it’s up to member states to implement the WHA resolution, moving beyond “siloed approaches” to NCDs to include liver health. Along with that, countries, supported by WHO, need to ensure more intentional tracking of liver health metrics: “What is not measured is ignored,” she said. Shift in populations at risk for liver diseases and liver cancers From left: Moderator Nicola Bedlington; Dr Pedro Gullón, Spanish Ministry of Health; Alison Cox, NCD Alliance; Prof Faisal Abaalkhail, Saudi Society for the Study of Liver Disease and Transplantation; Dr Kerri Elgar, OECD. In the Gulf region, like in Egypt, there has also been a shift in demand for liver transplants from people with viral hepatitis infections to individuals with SLDs, said Faisal Abaalkhail, president of the Saudi Society for the Study of Liver Disease and Transplantation, at the EASL event. He attributes this to the “huge rise” in obesity and diabetes. His patients are now also younger, something he calls “alarming.” Abaalkhail’s research and medical practice have pioneered liver transplants in the Gulf region. And in the past ten years, more than a third of the patients requiring liver transplants suffered from some form of SLD, he said. Early screening and detection are critical, he said, along with standardization of care for all SLD patients. “We often catch SLD too late,” said Abaalkhai. “We diagnose at the end with complications like cancer and liver failure.” But a greater emphasis on prevention is also important, he added. That includes better access to GLP-1 treatments for people who are obese or living with type 2 diabetes. With new treatments available, the region now needs to work on prioritizing exactly who can access them–including SLD patients through public health systems and insurance plans. See related story: WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug Need to integrate SLD into national NCD strategies The WHA resolution “highlights the growing recognition of the need to address metabolic conditions in a more integrated way,” said Dr Tedros Adhanom Ghebreyesus. “Metabolic conditions are becoming an increasingly important challenge globally,” he said in a message to the EASL event. “The rising prevalence of obesity, diabetes, cardiovascular and steatotic liver diseases, are driven by shared risk factors and determinants.” Added Henri Kluge, WHO European Regional Director: “Globally we are seeing the consequences of a rapidly changing metabolic disease landscape. Obesity, diabetes, cardiovascular diseases, chronic kidney disease and steatotic liver disease are on the rise – interconnected conditions shaped not only by biology but also by the unhealthy environments. “ Spain: tackling SLD as a ‘socially transmitted disease’ In Spain, steatotic liver disease historically has been under-recognized, although awareness is growing, noted Spain’s Director General of Public Health Pedro Gullón. In 2024, the Spanish Association for Liver Studies adopted the Spanish National Liver Health Plan, recognizing SLD as a public health threat and calling for better alignment with non-communicable disease (NCD) frameworks. Gullón is hopeful that the political momentum generated by the WHA resolution will prompt other member states to follow Spain’s example. Meanwhile, Spain is also passing new laws that should help prevent SLD. That includes stricter limits on alcohol consumption and displays in public places, particularly those frequented by children, like sports complexes, stadiums, and schools. Alcohol misuse is a leading cause of cirrhosis and liver cancer. “These are socially transmitted diseases,” Gullón observed. “When we do these kinds of policies, it’s not just for children, we are doing them for the whole population.” Closing the gap between WHA promises and delivery Despite this, civil society groups and watchdogs have been quick to point to the yawning gap between global health promises made by member states at the annual World Health Assembly and delivery on the ground in countries. Many of the same member states that co-sponsored the liver health resolution have struggled to control the overall rise of other NCDs, said Allison Cox, policy director of the NCD Alliance, at the EASL event. The NCD Alliance, which is tracking these disparities in its reporting, has argued for several measures to close this gap: protect policymakers from conflicts of interest, strengthen health care systems, and address the harmful commercial determinants of health. The UN General Assembly’s adoption in December 2025 of the High Level Declaration on NCDs and Mental Health is “encouraging”, Cox said. Formal adoption of the declaration from a meeting in September was delayed for several months by opposition from the United States. But, “targets don’t save lives. Implementation does,” Cox said. ‘Turning off the tap’- preventing a silent epidemic New OECD report cites a potential GDP gain of nearly 4% if leading NCD risks were eliminated, averting millions of deaths every year. The economic co-benefits of addressing liver health are also apparent, argued Kerri Elgar, senior global health advisor at the OECD. An OECD report published in April concluded that eliminating avoidable NCDs due to risks across six factors (air pollution, harmful alcohol use, unhealthy diet, obesity physical activity and smoking) would not only save millions of lives but also boost average GDP by 3.9%, on average across the 27 countries of the European Union, as well as reducing health expenditures by 40% between 2026-2050. Elgar noted the “synergies” between chronic diseases and the co-benefits with cardiovascular disease, diabetes, and other non-communicable diseases. Changing the environments that we live in is crucial to promoting prevention at these synergies, added Cox. “There’s the old public health adage that we need governments to move away from mopping the floor and turn off the tap,” she said in reference to tackling the upstream risks driving NCDs, including liver disease. “If they want to stop mopping that floor, that really means tackling commercial determinants of health,” Cox said. “Some of the most cost-effective ways of coping with noncommunicable diseases–like liver disease – is to tackle the modifiable risk factors: smoking, alcohol, unhealthy diets and air pollution, and the dominance of ultra-processed food.” Image Credits: Kenny Eliason/ Unsplash, Commons , EASL, Quora, Sophia Samantaroy/HPW , OECD, April 2026. How to Treat the Disinformation ‘Virus’ Undermining Health and Democracy 28/05/2026 Kerry Cullinan Disinformation proliferated during COVID-19 and became more organised and intent on undermining trust in science and institutions. The recent hantavirus outbreak triggered a wave of disinformation along similar lines to the COVID-19 pandemic: the virus was “fake”, “deliberately engineered”, and could be “cured” by Ivermectin. In the past week, furious community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital in the Democratic Republic of Congo (DRC) three times, motivated by misinformation and mistrust. While anti-science propaganda is not new, AI and social media platforms have enabled deliberate distortions (disinformation) and inaccurate information (misinformation) to proliferate instantly and at enormous scale. Health is one of the casualties of rising geopolitical division – from Russian bot farms spreading fake COVID-19 information to undermine Western governments, to Western leaders using slurs like “China virus” instead of coronavirus. Parts of the ‘Big Wellness’ sector are also actively undermining science-based medicines to drive people to their products. Threat to democracy Céline Jurgensen, France’s Ambassador to the UN in Geneva. Céline Jurgensen, France’s Ambassador to Geneva, describes the rapid spread of false information and disinformation as a challenge for both “health security and democratic resilience”. Post-COVID, there is “increased mistrust towards health authorities, questioning of vaccine policies, and weakening trust in science”, she said. “This phenomenon has become broader. It’s become ideological, and it’s sometimes institutionalised in its orchestration,” Jurgensen told a roundtable on dis- and misinformation at last week’s World Health Assembly. Many of the narratives are “anti-system, anti-science” aimed at “creating broad mistrust in public authorities, international organisations including the UN, and researchers”. Helen Clark, chair of the vaccine platform Gavi and former Prime Minister of New Zealand, calls mis- and disinformation “an existential threat to public health”, representing a “crisis of trust”. “We see less trust in institutions, science, and vaccines. We see polarisation. We see the disinformation actors who exploit and profit from what they do. We see people using AI chatbots and search engines for health information.” Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer, described misinformation and disinformation as “anti-system, is anti-multilateralism, and anti democratic”, requiring solutions that address all these areas, including health. “The advances that we’ve made in sexual reproductive health and rights, maternal health, and child health have been driven primarily by evidence, and there is a concentrated effort to erode that evidence,” said Akinfaderin. “We have seen concentrated strategic efforts by anti-rights and anti-gender actors, particularly, to undermine scientific evidence and to create distrust in the system.” Influencing health outcomes Robert Mardini, Director General of Geneva University Hospitals. “Misinformation and disinformation are no longer sitting at the periphery of our challenges, but very much at the core, front and centre of the daily humanitarian response, but also clinical realities,” said Robert Mardini, Director General of Geneva University Hospitals and former head of the International Committee of the Red Cross. “They influence how patients interpret their symptoms, whether they are they seek care, how they adhere to treatments, and how communities respond to public health recommendations.” Examples of disinformation are easy to find. Last year, Pakistan introduced the HPV vaccine, which protects against cervical cancer. “Gavi research found that vaccine-related search of videos on Facebook in Urdu returned vaccine misinformation in 27% of the top-ranked videos, compared to 17% in support of the vaccine,” said Clark. During COVID-19, a fake letter falsely attributed to a senior physician at the Geneva University Hospital claimed that the vaccine caused infertility, said Mardini. “In another case, national public health guidance was distorted and went global, falsely suggesting that Switzerland had declared vaccines dangerous,” he added. Akinfaderin has been confronted with claims in Nigeria and Uganda that contraceptives are linked to infertility and cervical cancer, some even spread by women’s rights organisations. Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer. Brazil’s Secretary of Health, Dr Mariângela Simão, said her country was still dealing with vaccine hesitancy from when Jair Bolsonaro was the president and “was a denialist right of both the pandemic and of vaccines”. Prof Alexandra Calmy, who heads the HIV unit at the University of Geneva Hospital, said that the day after US President Donald Trump suggested a link between paracetamol and autism in pregnant women, patients at her clinic refused pain relief. A trust problem “Misinformation is not primarily a communication challenge. It is a trust problem,” said Mardini. “Trust must be treated as a strategic public asset,” said Dr Sopon Iamsirithaworn, Deputy Secretary of Thailand’s Ministry of Public Health. “People don’t follow health measures just because they receive information. What really matters is whether they trust the system and believe in the message they hear.” But, he added, in Thailand “trust doesn’t come from the centre alone. It is built at the community level with trusted people on the ground, including our village health volunteers who live in the community”. Health authorities and governments are no match for the speed and scale at which chatbots and generative AI can generate fake information. But there are tools to dismantle some fake news. Regulating tech platforms Clark stresses increased access to “quality health information”, a “much better understanding of the real impact of mis- and disinformation on health incomes”, and holding tech platforms accountable for their role in purveying misinformation. “What might regulators insist that they do to clean up their act and stop being the purveyors of the kind of mis and disinformation that is going to cost people’s lives and health?” she asks. France has a national strategy for combating disinformation in health, which could inspire some other countries, says Jergensen. The European Union’s Digital Services Act seeks to “strengthen the responsibility of digital platforms” to clamp down on the spread of illicit or misleading content, she points out. “We also need to strengthen regional and international ways that we share information, and to cooperate in early warnings.” Simão notes that, in Brazil’s National Health System in Brazil, there is a legal requirement f to have civil society participation. Iamsirithaworn stresses speedy responses to misinformation and strengthening governments’ “social listening capacity” to understand what people are hearing and thinking. Akinfaderin calls for strengthened capacity, particularly in the global south, to challenge the notion that being anti-science is akin to decolonisation. ‘Together for Science and Health’ WHO Chief Scientist Sylvie Briand WHO Chief Scientist Sylvie Briand stresses the need to “listen, connect, and communicate”. Her division aims to launch a movement called ‘Together for Science and Health’ to address mis- and disinformation. Mardini acknowledges that misinformation spreads “faster than our collective ability to counter it” “We will not solve disinformation by correcting falsehood faster. We must build systemic resilience by strengthening scientific literacy, investing in transparency, reinforcing links between science and communities, and working through trusted international networks. He also calls for “supporting healthcare workers as trusted communicators”, as they are “the most credible interface between science and society, but they need time, training and institutional backing to play this role”. “Ultimately, the question is not only how we fight misinformation and disinformation, but whether we create environments where it cannot easily take root and spread.” Image Credits: EU vs DiSiNFO. Africa CDC Chief Condemns Ebola Travel Restrictions and Broken Aid Promises 28/05/2026 Kerry Cullinan Africa CDC Director General Dr Jean Kaseya International Ebola-related travel restrictions imposed on people from the Democratic Republic of Congo (DRC), Uganda and South Sudan – which has yet to record a single case – are “unacceptable” will have a detrimental effect on the economies of affected countries, said Dr Jean Kaseya, head of the Africa Centres for Disease Control and Prevention on Thursday. The US was the first to ban travellers from the three countries, with Canada, the Bahamas, Jordan and Bahrain following, but Kaseya said 15 countries have now imposed some form of travel restrictions. “We cannot stop this outbreak with travel restrictions that Western countries have started to impose on African countries. It even a shame to see a country like South Sudan, with zero suspected cases and zero deaths, under travel restriction. The treatment that Western countries are applying to Africa… it’s not acceptable,” said Kaseya, speaking from the DRC’s capital, Kinshasa. During the last large Ebola outbreak in 2018, West Africa lost $53 billion or 12% of their GDP, said Kaseya. By Wednesday, there were 1077 suspected cases in the DRC and 246 deaths, including “three very young doctors” in Bunia in Ituri province, the epicentre of the outbreak, Kaseya reported. However, more cases are expected as given that the outbreak is centred in a remote and conflict-ridden, Two countries are affected but 11 countries on their borders are at risk, and Africa CDC is also working with these countries to strengthen their surveillance capacity. “Tomorrow, I will be in Burundi meeting the president and senior officials to see how the country is getting ready if the cases that we have in South Kivu [in neighbouring DRC] are detected also in Burundi. This is why we are really running –l et me correct myself, we are not running, we are flying – to make sure that we can stop this outbreak very quickly.” ‘Mistrust of Western countries’ Kaseya said that he had visited Bunia in the last few days where he encountered “mistrust of Western countries” by people in the area. “The question they are asking me is: ‘DG, why after 19 years of this [disease], we still don’t have a vaccine, we still don’t have medicine? A local leader was telling me: ‘If this outbreak was in Europe or in the US, a vaccine and medicines will already be available’,” Kaseya told the media briefing. Kaseya also condemned countries that had pledged financial support for the outbreak effort only to renege a few days later, saying that he would name them within a week if they did not make good on their promises. The DRC will contribute $50 million to the effort, but the need is in the region of $319 million. “On Monday (25 May), we ended the day with a pledge of $498.8 million almost $500 million Since then the figure is going down. Now, as I’m talking to you, the figure is around $290 million We cannot afford to stop this outbreak without resources. We cannot afford to stop this outbreak just with political declaration from some countries,” he said. Africa CDC has developed a list of priority tasks for all affected sectors, making a particular appeal to communities to trust and protect health workers. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. Kaseya said that churches and local radio stations were being mobilised to assist to reach affected communities and provide them with accurate information about the disease and their risks. The US State Department announced on Thursday that it has “mobilized more than $112 million in bilateral foreign assistance for the Ebola response in less than two weeks”, with an additional $80 million in bilateral assistance to key partners finalised this week. “These new resources will enable implementing partners to scale up the following critical response activities: PPE procurement and delivery, border screening and surveillance, contact tracing, and diagnostics supplies,” the US State Department said. WHO Calls for ‘Immediate Ceasefire’ to Enable Ebola Response 28/05/2026 Kerry Cullinan Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients. The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”. The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday. The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals. “Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned. The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths. However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. “We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.” Travel restrictions Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home. This week, Canada also closed its borders to the same three countries. However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”. The ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”. It has also deployed an ECDC expert to the Africa CDC to support its response. Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult. Race for vaccines, treatment Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak. There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period. Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately. Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies. The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS. But this has to be injected, making it less suitable for remote areas such as Ituri. Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US. The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients. Image Credits: AP, Africa CDC. Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
Congo Ebola Outbreak Now Third-Largest on Record as Suspected Cases Pass 1,000 01/06/2026 Stefan Anderson Health workers in the DRC put together protective gear during an Ebola outbreak in 2019. A rare and deadly strain of the Ebola virus is spreading rapidly through a region of the Democratic Republic of the Congo (DRC) that has never previously experienced the disease, pushing suspected cases past 1,000 this week amid severe logistical hurdles and mounting community resistance. The outbreak, caused by the Bundibugyo version of the virus, has claimed at least 246 lives in the DRC since it first emerged in early May. Three Red Cross volunteers are among the dead after contracting the virus while managing the bodies of Ebola victims without adequate protective gear before the outbreak was detected. The Ministry of Health in the DRC described the outbreak in a joint statement with the World Health Organization (WHO) late Sunday as “a rapidly evolving situation, with cases and deaths notified in several health zones” across Ituri, North Kivu and South Kivu. “Persistent challenges include early detection and isolation of cases, contact tracing, safe and dignified burials, robust infection prevention and control in health facilities, and strong community awareness,” the ministry added. Medical charity Médecins Sans Frontières warned that the true scale of the crisis remains unknown, calling the situation “deeply alarming.” “The reality today is that nobody knows the true scale and severity of this outbreak. New suspected cases are being reported daily, yet hundreds of samples remain untested,” said Dr Alan Gonzalez, deputy director of MSF. “Never before has an Ebola outbreak recorded so many cases so soon after its declaration.” The crisis currently ranks as the third-largest Ebola outbreak on record based on confirmed and suspected cases, and the virus has already crossed borders, with neighboring Uganda reporting nine confirmed cases and one death. WHO Director-General Dr Tedros Adhanom Ghebreyesus traveled to Bunia, the epicenter of the outbreak, to oversee the international response on the ground. “I wish the circumstances were different, but I came because the people of Ituri, the Kivus, and all of DRC deserve to know they are not alone,” Tedros said. Prior to arriving in Bunia, Tedros met with Prime Minister Judith Suminwa Tuluka in Kinshasa to coordinate the government-led response. He is scheduled to hold subsequent meetings with local ministers, the provincial governor, the Congolese Red Cross, Africa CDC, UNICEF and the World Food Programme. “DRC has faced Ebola before, sixteen times, and has ended every outbreak,” Tedros said. “This is the seventeenth. That history gives me real confidence.” ‘Not here to tell people what to do’ The recent Ebola outbreak serves as a grim reminder that nature does not wait for treaty negotiations. The outbreak is centered in Ituri Province, a region already beset by food insecurity and clashes between armed groups. While eastern DRC cities just five to seven hours away have battled the virus before, Ituri has no history of the disease. Because residents lack the instincts and training to identify or manage the illness, the sudden arrival of international medical personnel enforcing strict infection protocols has sparked a mixed and sometimes hostile local response. Much of this mistrust stems from the grim reality of Ebola containment, which requires isolating the sick and strictly prohibiting families from interacting with their deceased loved ones due to the danger of infection. The bodies of Ebola victims remain highly infectious after death. Traditional funeral rites in the region, during which mourners touch and wash the deceased, have been a persistent driver of transmission in past outbreaks. While health guidelines mandate that trained teams conduct these “safe and dignified” burials, convincing the local population to set aside their deeply held rituals and hand over their loved ones to foreigners in protective suits has proven incredibly difficult. Distribution of suspected and confirmed cases of Bundibugyo virus disease in Democratic Republic of the Congo and Uganda, as of 29 May 2026. Tedros addressed this gulf between community sentiment and the harsh necessity of the outbreak response, acknowledging the cultural friction surrounding the handling of the dead. “Safe, dignified burials matter too. I understand how painful it is to lose someone, and how much it means to honour them properly,” Tedros said. “But certain practices, including touching the bodies of those who have died from Ebola, can spread the virus further. While we grieve for those we have lost, we must do everything we can so that we do not lose another.” He added that the World Health Organization’s goal is to act as a partner, rather than an enforcer, in the region. “We are not here to tell people what to do. We are here to listen,” he said. “Communities understand their own challenges and their own solutions. Our role is to support you in implementing those solutions, together. Community ownership is what will bring this outbreak to an end. “ Doctors in the DRC reported three attacks on health facilities treating Ebola patients in Ituri over the weekend. The violence is largely driven by civilians angry over not being able to bury dead family members, alongside a smaller faction, estimated at about one in four by The Lancet, who believe the outbreak is a hoax. The hostility echoes the severe violence directed at health workers during the 2018-2020 Ebola outbreak in neighboring North Kivu, where armed attacks on treatment centers repeatedly forced medical teams to suspend operations and resulted in multiple fatalities among responders. What happened? Number of confirmed cases (n=125) and deaths (n=17) by date of reporting in the Democratic Republic of the Congo as of 27 May 2026. Unlike the more commonly known Ebola and Sudan viruses, there is no approved vaccine or preventive treatment for the Bundibugyo strain, forcing medical teams to focus entirely on managing patient symptoms and treating other underlying diseases. Confirming a diagnosis requires special test kits specific to the individual virus strain, largely because Ebola shares early symptoms with other illnesses endemic to eastern DRC, such as malaria and typhoid. However, kits for the Bundibugyo virus are currently in short supply, significantly slowing case confirmation and subsequently delaying contact tracing and patient isolation. “This outbreak is unfolding in a context where medical needs are already acute, and we are now at real risk of a silent escalation of other critical health problems people face every day,” Gonzalez said. “So many health facilities are overwhelmed, and access to regular, non-Ebola care is affected while many people remain at home, too afraid to seek care.” The African Union estimates that approximately $264 million will be required for response operations in the DRC and Uganda to contain the virus, with an additional $54 million needed to strengthen preparedness across neighboring high-risk countries, including South Sudan. Officials caution the figures are preliminary and could increase as the outbreak progresses. Tedros emphasized that the WHO will continue to coordinate closely with the DRC government, stressing that emergency investments made during the current crisis must be leveraged to fortify the country’s health infrastructure for the future, a sentiment the DRC Health Ministry in its joint statement. Support will continue after the outbreak ends and the public health emergency declared by the UN Health agency draws to a close. “Our commitment doesn’t end when an outbreak does,” Tedros said. “We want to leave behind health workers, hospitals, laboratories and services that will serve the people of Ituri for many years to come.” Border shutdown stokes shortage fears 'We saw Ebola patients trying to push though to come into our country'Uganda Permanent Secretary for Health Dr Diana Atwine tells Focus On Africa's Waihiga Mwaura that her country closed the borders with the DRC to try and contain the current Ebola outbreak. pic.twitter.com/dtWv5Nzqjw — BBC News Africa (@BBCAfrica) May 28, 2026 The international response is currently being hindered by critical supply shortages, complex travel restrictions and partial border closures in place between Congo, Uganda and Rwanda. Movement is restricted in and out of the airport in Bunia, an early center of the outbreak, and the city of Goma on the Rwandan border. While most border closures include loopholes to allow humanitarian aid to pass, the reality on the ground is more complex, and aid workers frequently do not know if they will be permitted to cross a frontier until they arrive at a checkpoint. These travel restrictions compound existing logistical challenges in a region characterised by rudimentary road infrastructure and the presence of rebel groups, delaying the arrival of specialist personnel and leaving the delivery of protective equipment, medical supplies and food in doubt. MSF noted from experience that border and airport closures severely hinder outbreak responses and isolate countries that urgently require international support. As suspected case numbers continue to rise, aid staff are increasingly concerned that food, medicines and protective equipment will become more expensive and difficult to source. “You can’t expect a big Ebola response and then not let people out of the province,” Trish Newport, Médecins Sans Frontières’ emergency-program manager told Bloomberg. Image Credits: John Wessels/ MSF, Joël Lumbala/ WHO. Historic WHA Resolution on Fatty Liver Disease Opens Door for Integration into National NCD Strategies 29/05/2026 Sophia Samantaroy Steatotic liver disease, commonly known as fatty liver disease, is linked to the same risk factors that cause other leading NCDs – unhealthy diets, obesity, tobacco use and alcohol misuse. Steatotic liver disease (SLD) was recognized as a “missing piece” of the global noncommunicable disease response in a milestone World Health Assembly resolution last week. With countries making extraordinary progress in combating viral hepatitis, SLD, formerly known as fatty liver disease, is now the fastest-growing chronic liver disease – but far less recognized. Experts and advocates believe the new World Health Asssembly (WHA) decision will trigger more awareness and action in countries and globally. GENEVA– The WHA’s resolution recognizing steatotic liver disease (fatty liver) as an NCD is a long-awaited milestone for a chronic liver condition that carries a huge global health burden but is dramatically under-recognized, experts and patient advocates say. “What we aimed to do is get SLD recognized as a non-communicable disease,” Debbie Shawcross, Secretary General of the European Society for the Study of the Liver (EASL) told Health Policy Watch. “Because we know in these populations, people don’t just suffer from liver disease. They also have cardiovascular disease, chronic kidney disease, diabetes, and more.” Debbie Shawcross, Secretary General, EASL Until very recently, the biggest focus for liver disease was viral hepatitis: “Rightly so, all our resources went into the pandemic of hepatitis C and B.” But now with vaccines for hep B and an antiviral cure for hep C, “we are realizing that what is left behind is a disease that is unaddressed and accelerating.” Shawcross spoke at a high level side event sponsored by EASL last Thursday, the same day that the new resolution was approved by WHA. The event included experts from EASL’s Saudi Arabia affiliate, the NCD Alliance and the Organization of Economic Co-Operation and Development (OECD), as well as Spain’s Director General of Public Health and the Minister of Health from Egypt, which co-sponsored the WHA resolution along with 15 other countries. Egypt: a ‘missing piece’ in the global NCD response Professor Khaled Abdel-Gaffar, Minister of Health, Egypt. The rapid rise in metabolic liver disorders represents the “next great public health challenge,” said Khaled Abdel Ghaffar, Egyptian Minister of Health, at the EASL event. Egypt was one of the first WHO member states to sound the global health alarm around SLD after having grappled years earlier with some of the world’s highest rates of hepatitis C infection – and related viral liver disease burden. What followed was a landmark national campaign to eradicate hep C. But Egypt also suffers from a growing prevalence of diabetes, obesity, and cardiovascular disease – all risk factors for SLD. So early on, it became a champion for recognition of the liver disease as an important NCD. “Building on our experience and recognizing this urgent global need, Egypt has taken another decisive step in leadership,” said Ghaffar. “We proudly sponsored the landmark WHO resolution steatotic liver disease, a missing piece in the global non-communicable disease response.” Growing SLD burden closely linked to diabetes and obesity Comparison of a healthy liver and one with SLD, commonly known as fatty liver disease. SLD affects an estimated 1.7 billion adults globally – who suffer from the metabolic-associated liver dysfunction. In WHO’s European region alone, some 800,000 people die of advanced liver disease each year – costing some $64 billion annually. Its former name, fatty liver disease, remains in fact, an apt description of the condition insofar as SLD is linked to an excess build up of fat in the liver. This may be due to heavy alcohol use or to metabolic dysfunctions related to other NCDs, such as: obesity, insulin resistance, hyperglycemia or pre-diabetes, high cholesterol levels, and hypertension. With few early warning signs, the disease can quickly progress to severe inflammation, cirrhosis, and liver cancer. Globally, the number of new cases of liver cancers have already increased by 50% in the past decade–and are expected to double by 2050. Experts point to SLD as now a major cause of the current surge of liver cancer–which is in turn fueled by rising obesity and diabetes rates. The resolution highlights the shared NCD risk factors characteristic to the development of SLDs, including unhealthy diets, air pollution, smoking, physical inactivity and consequent obesity, as well as harmful alcohol use. It officially incorporates SLD into the broader umbrella of NCDs addressed by the global health agency. Member states are urged to integrate SLD into their noncommunicable disease strategies through strengthened prevention, early detection, primary care services, and public awareness. And the resolution calls on WHO to support research, surveillance, and equitable access to diagnostics and treatment. “For the first time, liver disease receives formal recognition within the global noncommunicable disease agenda,” EASL said in a statement, hailing the resolution as a “turning point” for liver health worldwide. Now, said Shawcross, it’s up to member states to implement the WHA resolution, moving beyond “siloed approaches” to NCDs to include liver health. Along with that, countries, supported by WHO, need to ensure more intentional tracking of liver health metrics: “What is not measured is ignored,” she said. Shift in populations at risk for liver diseases and liver cancers From left: Moderator Nicola Bedlington; Dr Pedro Gullón, Spanish Ministry of Health; Alison Cox, NCD Alliance; Prof Faisal Abaalkhail, Saudi Society for the Study of Liver Disease and Transplantation; Dr Kerri Elgar, OECD. In the Gulf region, like in Egypt, there has also been a shift in demand for liver transplants from people with viral hepatitis infections to individuals with SLDs, said Faisal Abaalkhail, president of the Saudi Society for the Study of Liver Disease and Transplantation, at the EASL event. He attributes this to the “huge rise” in obesity and diabetes. His patients are now also younger, something he calls “alarming.” Abaalkhail’s research and medical practice have pioneered liver transplants in the Gulf region. And in the past ten years, more than a third of the patients requiring liver transplants suffered from some form of SLD, he said. Early screening and detection are critical, he said, along with standardization of care for all SLD patients. “We often catch SLD too late,” said Abaalkhai. “We diagnose at the end with complications like cancer and liver failure.” But a greater emphasis on prevention is also important, he added. That includes better access to GLP-1 treatments for people who are obese or living with type 2 diabetes. With new treatments available, the region now needs to work on prioritizing exactly who can access them–including SLD patients through public health systems and insurance plans. See related story: WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug Need to integrate SLD into national NCD strategies The WHA resolution “highlights the growing recognition of the need to address metabolic conditions in a more integrated way,” said Dr Tedros Adhanom Ghebreyesus. “Metabolic conditions are becoming an increasingly important challenge globally,” he said in a message to the EASL event. “The rising prevalence of obesity, diabetes, cardiovascular and steatotic liver diseases, are driven by shared risk factors and determinants.” Added Henri Kluge, WHO European Regional Director: “Globally we are seeing the consequences of a rapidly changing metabolic disease landscape. Obesity, diabetes, cardiovascular diseases, chronic kidney disease and steatotic liver disease are on the rise – interconnected conditions shaped not only by biology but also by the unhealthy environments. “ Spain: tackling SLD as a ‘socially transmitted disease’ In Spain, steatotic liver disease historically has been under-recognized, although awareness is growing, noted Spain’s Director General of Public Health Pedro Gullón. In 2024, the Spanish Association for Liver Studies adopted the Spanish National Liver Health Plan, recognizing SLD as a public health threat and calling for better alignment with non-communicable disease (NCD) frameworks. Gullón is hopeful that the political momentum generated by the WHA resolution will prompt other member states to follow Spain’s example. Meanwhile, Spain is also passing new laws that should help prevent SLD. That includes stricter limits on alcohol consumption and displays in public places, particularly those frequented by children, like sports complexes, stadiums, and schools. Alcohol misuse is a leading cause of cirrhosis and liver cancer. “These are socially transmitted diseases,” Gullón observed. “When we do these kinds of policies, it’s not just for children, we are doing them for the whole population.” Closing the gap between WHA promises and delivery Despite this, civil society groups and watchdogs have been quick to point to the yawning gap between global health promises made by member states at the annual World Health Assembly and delivery on the ground in countries. Many of the same member states that co-sponsored the liver health resolution have struggled to control the overall rise of other NCDs, said Allison Cox, policy director of the NCD Alliance, at the EASL event. The NCD Alliance, which is tracking these disparities in its reporting, has argued for several measures to close this gap: protect policymakers from conflicts of interest, strengthen health care systems, and address the harmful commercial determinants of health. The UN General Assembly’s adoption in December 2025 of the High Level Declaration on NCDs and Mental Health is “encouraging”, Cox said. Formal adoption of the declaration from a meeting in September was delayed for several months by opposition from the United States. But, “targets don’t save lives. Implementation does,” Cox said. ‘Turning off the tap’- preventing a silent epidemic New OECD report cites a potential GDP gain of nearly 4% if leading NCD risks were eliminated, averting millions of deaths every year. The economic co-benefits of addressing liver health are also apparent, argued Kerri Elgar, senior global health advisor at the OECD. An OECD report published in April concluded that eliminating avoidable NCDs due to risks across six factors (air pollution, harmful alcohol use, unhealthy diet, obesity physical activity and smoking) would not only save millions of lives but also boost average GDP by 3.9%, on average across the 27 countries of the European Union, as well as reducing health expenditures by 40% between 2026-2050. Elgar noted the “synergies” between chronic diseases and the co-benefits with cardiovascular disease, diabetes, and other non-communicable diseases. Changing the environments that we live in is crucial to promoting prevention at these synergies, added Cox. “There’s the old public health adage that we need governments to move away from mopping the floor and turn off the tap,” she said in reference to tackling the upstream risks driving NCDs, including liver disease. “If they want to stop mopping that floor, that really means tackling commercial determinants of health,” Cox said. “Some of the most cost-effective ways of coping with noncommunicable diseases–like liver disease – is to tackle the modifiable risk factors: smoking, alcohol, unhealthy diets and air pollution, and the dominance of ultra-processed food.” Image Credits: Kenny Eliason/ Unsplash, Commons , EASL, Quora, Sophia Samantaroy/HPW , OECD, April 2026. How to Treat the Disinformation ‘Virus’ Undermining Health and Democracy 28/05/2026 Kerry Cullinan Disinformation proliferated during COVID-19 and became more organised and intent on undermining trust in science and institutions. The recent hantavirus outbreak triggered a wave of disinformation along similar lines to the COVID-19 pandemic: the virus was “fake”, “deliberately engineered”, and could be “cured” by Ivermectin. In the past week, furious community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital in the Democratic Republic of Congo (DRC) three times, motivated by misinformation and mistrust. While anti-science propaganda is not new, AI and social media platforms have enabled deliberate distortions (disinformation) and inaccurate information (misinformation) to proliferate instantly and at enormous scale. Health is one of the casualties of rising geopolitical division – from Russian bot farms spreading fake COVID-19 information to undermine Western governments, to Western leaders using slurs like “China virus” instead of coronavirus. Parts of the ‘Big Wellness’ sector are also actively undermining science-based medicines to drive people to their products. Threat to democracy Céline Jurgensen, France’s Ambassador to the UN in Geneva. Céline Jurgensen, France’s Ambassador to Geneva, describes the rapid spread of false information and disinformation as a challenge for both “health security and democratic resilience”. Post-COVID, there is “increased mistrust towards health authorities, questioning of vaccine policies, and weakening trust in science”, she said. “This phenomenon has become broader. It’s become ideological, and it’s sometimes institutionalised in its orchestration,” Jurgensen told a roundtable on dis- and misinformation at last week’s World Health Assembly. Many of the narratives are “anti-system, anti-science” aimed at “creating broad mistrust in public authorities, international organisations including the UN, and researchers”. Helen Clark, chair of the vaccine platform Gavi and former Prime Minister of New Zealand, calls mis- and disinformation “an existential threat to public health”, representing a “crisis of trust”. “We see less trust in institutions, science, and vaccines. We see polarisation. We see the disinformation actors who exploit and profit from what they do. We see people using AI chatbots and search engines for health information.” Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer, described misinformation and disinformation as “anti-system, is anti-multilateralism, and anti democratic”, requiring solutions that address all these areas, including health. “The advances that we’ve made in sexual reproductive health and rights, maternal health, and child health have been driven primarily by evidence, and there is a concentrated effort to erode that evidence,” said Akinfaderin. “We have seen concentrated strategic efforts by anti-rights and anti-gender actors, particularly, to undermine scientific evidence and to create distrust in the system.” Influencing health outcomes Robert Mardini, Director General of Geneva University Hospitals. “Misinformation and disinformation are no longer sitting at the periphery of our challenges, but very much at the core, front and centre of the daily humanitarian response, but also clinical realities,” said Robert Mardini, Director General of Geneva University Hospitals and former head of the International Committee of the Red Cross. “They influence how patients interpret their symptoms, whether they are they seek care, how they adhere to treatments, and how communities respond to public health recommendations.” Examples of disinformation are easy to find. Last year, Pakistan introduced the HPV vaccine, which protects against cervical cancer. “Gavi research found that vaccine-related search of videos on Facebook in Urdu returned vaccine misinformation in 27% of the top-ranked videos, compared to 17% in support of the vaccine,” said Clark. During COVID-19, a fake letter falsely attributed to a senior physician at the Geneva University Hospital claimed that the vaccine caused infertility, said Mardini. “In another case, national public health guidance was distorted and went global, falsely suggesting that Switzerland had declared vaccines dangerous,” he added. Akinfaderin has been confronted with claims in Nigeria and Uganda that contraceptives are linked to infertility and cervical cancer, some even spread by women’s rights organisations. Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer. Brazil’s Secretary of Health, Dr Mariângela Simão, said her country was still dealing with vaccine hesitancy from when Jair Bolsonaro was the president and “was a denialist right of both the pandemic and of vaccines”. Prof Alexandra Calmy, who heads the HIV unit at the University of Geneva Hospital, said that the day after US President Donald Trump suggested a link between paracetamol and autism in pregnant women, patients at her clinic refused pain relief. A trust problem “Misinformation is not primarily a communication challenge. It is a trust problem,” said Mardini. “Trust must be treated as a strategic public asset,” said Dr Sopon Iamsirithaworn, Deputy Secretary of Thailand’s Ministry of Public Health. “People don’t follow health measures just because they receive information. What really matters is whether they trust the system and believe in the message they hear.” But, he added, in Thailand “trust doesn’t come from the centre alone. It is built at the community level with trusted people on the ground, including our village health volunteers who live in the community”. Health authorities and governments are no match for the speed and scale at which chatbots and generative AI can generate fake information. But there are tools to dismantle some fake news. Regulating tech platforms Clark stresses increased access to “quality health information”, a “much better understanding of the real impact of mis- and disinformation on health incomes”, and holding tech platforms accountable for their role in purveying misinformation. “What might regulators insist that they do to clean up their act and stop being the purveyors of the kind of mis and disinformation that is going to cost people’s lives and health?” she asks. France has a national strategy for combating disinformation in health, which could inspire some other countries, says Jergensen. The European Union’s Digital Services Act seeks to “strengthen the responsibility of digital platforms” to clamp down on the spread of illicit or misleading content, she points out. “We also need to strengthen regional and international ways that we share information, and to cooperate in early warnings.” Simão notes that, in Brazil’s National Health System in Brazil, there is a legal requirement f to have civil society participation. Iamsirithaworn stresses speedy responses to misinformation and strengthening governments’ “social listening capacity” to understand what people are hearing and thinking. Akinfaderin calls for strengthened capacity, particularly in the global south, to challenge the notion that being anti-science is akin to decolonisation. ‘Together for Science and Health’ WHO Chief Scientist Sylvie Briand WHO Chief Scientist Sylvie Briand stresses the need to “listen, connect, and communicate”. Her division aims to launch a movement called ‘Together for Science and Health’ to address mis- and disinformation. Mardini acknowledges that misinformation spreads “faster than our collective ability to counter it” “We will not solve disinformation by correcting falsehood faster. We must build systemic resilience by strengthening scientific literacy, investing in transparency, reinforcing links between science and communities, and working through trusted international networks. He also calls for “supporting healthcare workers as trusted communicators”, as they are “the most credible interface between science and society, but they need time, training and institutional backing to play this role”. “Ultimately, the question is not only how we fight misinformation and disinformation, but whether we create environments where it cannot easily take root and spread.” Image Credits: EU vs DiSiNFO. Africa CDC Chief Condemns Ebola Travel Restrictions and Broken Aid Promises 28/05/2026 Kerry Cullinan Africa CDC Director General Dr Jean Kaseya International Ebola-related travel restrictions imposed on people from the Democratic Republic of Congo (DRC), Uganda and South Sudan – which has yet to record a single case – are “unacceptable” will have a detrimental effect on the economies of affected countries, said Dr Jean Kaseya, head of the Africa Centres for Disease Control and Prevention on Thursday. The US was the first to ban travellers from the three countries, with Canada, the Bahamas, Jordan and Bahrain following, but Kaseya said 15 countries have now imposed some form of travel restrictions. “We cannot stop this outbreak with travel restrictions that Western countries have started to impose on African countries. It even a shame to see a country like South Sudan, with zero suspected cases and zero deaths, under travel restriction. The treatment that Western countries are applying to Africa… it’s not acceptable,” said Kaseya, speaking from the DRC’s capital, Kinshasa. During the last large Ebola outbreak in 2018, West Africa lost $53 billion or 12% of their GDP, said Kaseya. By Wednesday, there were 1077 suspected cases in the DRC and 246 deaths, including “three very young doctors” in Bunia in Ituri province, the epicentre of the outbreak, Kaseya reported. However, more cases are expected as given that the outbreak is centred in a remote and conflict-ridden, Two countries are affected but 11 countries on their borders are at risk, and Africa CDC is also working with these countries to strengthen their surveillance capacity. “Tomorrow, I will be in Burundi meeting the president and senior officials to see how the country is getting ready if the cases that we have in South Kivu [in neighbouring DRC] are detected also in Burundi. This is why we are really running –l et me correct myself, we are not running, we are flying – to make sure that we can stop this outbreak very quickly.” ‘Mistrust of Western countries’ Kaseya said that he had visited Bunia in the last few days where he encountered “mistrust of Western countries” by people in the area. “The question they are asking me is: ‘DG, why after 19 years of this [disease], we still don’t have a vaccine, we still don’t have medicine? A local leader was telling me: ‘If this outbreak was in Europe or in the US, a vaccine and medicines will already be available’,” Kaseya told the media briefing. Kaseya also condemned countries that had pledged financial support for the outbreak effort only to renege a few days later, saying that he would name them within a week if they did not make good on their promises. The DRC will contribute $50 million to the effort, but the need is in the region of $319 million. “On Monday (25 May), we ended the day with a pledge of $498.8 million almost $500 million Since then the figure is going down. Now, as I’m talking to you, the figure is around $290 million We cannot afford to stop this outbreak without resources. We cannot afford to stop this outbreak just with political declaration from some countries,” he said. Africa CDC has developed a list of priority tasks for all affected sectors, making a particular appeal to communities to trust and protect health workers. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. Kaseya said that churches and local radio stations were being mobilised to assist to reach affected communities and provide them with accurate information about the disease and their risks. The US State Department announced on Thursday that it has “mobilized more than $112 million in bilateral foreign assistance for the Ebola response in less than two weeks”, with an additional $80 million in bilateral assistance to key partners finalised this week. “These new resources will enable implementing partners to scale up the following critical response activities: PPE procurement and delivery, border screening and surveillance, contact tracing, and diagnostics supplies,” the US State Department said. WHO Calls for ‘Immediate Ceasefire’ to Enable Ebola Response 28/05/2026 Kerry Cullinan Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients. The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”. The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday. The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals. “Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned. The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths. However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. “We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.” Travel restrictions Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home. This week, Canada also closed its borders to the same three countries. However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”. The ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”. It has also deployed an ECDC expert to the Africa CDC to support its response. Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult. Race for vaccines, treatment Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak. There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period. Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately. Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies. The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS. But this has to be injected, making it less suitable for remote areas such as Ituri. Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US. The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients. Image Credits: AP, Africa CDC. Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
Historic WHA Resolution on Fatty Liver Disease Opens Door for Integration into National NCD Strategies 29/05/2026 Sophia Samantaroy Steatotic liver disease, commonly known as fatty liver disease, is linked to the same risk factors that cause other leading NCDs – unhealthy diets, obesity, tobacco use and alcohol misuse. Steatotic liver disease (SLD) was recognized as a “missing piece” of the global noncommunicable disease response in a milestone World Health Assembly resolution last week. With countries making extraordinary progress in combating viral hepatitis, SLD, formerly known as fatty liver disease, is now the fastest-growing chronic liver disease – but far less recognized. Experts and advocates believe the new World Health Asssembly (WHA) decision will trigger more awareness and action in countries and globally. GENEVA– The WHA’s resolution recognizing steatotic liver disease (fatty liver) as an NCD is a long-awaited milestone for a chronic liver condition that carries a huge global health burden but is dramatically under-recognized, experts and patient advocates say. “What we aimed to do is get SLD recognized as a non-communicable disease,” Debbie Shawcross, Secretary General of the European Society for the Study of the Liver (EASL) told Health Policy Watch. “Because we know in these populations, people don’t just suffer from liver disease. They also have cardiovascular disease, chronic kidney disease, diabetes, and more.” Debbie Shawcross, Secretary General, EASL Until very recently, the biggest focus for liver disease was viral hepatitis: “Rightly so, all our resources went into the pandemic of hepatitis C and B.” But now with vaccines for hep B and an antiviral cure for hep C, “we are realizing that what is left behind is a disease that is unaddressed and accelerating.” Shawcross spoke at a high level side event sponsored by EASL last Thursday, the same day that the new resolution was approved by WHA. The event included experts from EASL’s Saudi Arabia affiliate, the NCD Alliance and the Organization of Economic Co-Operation and Development (OECD), as well as Spain’s Director General of Public Health and the Minister of Health from Egypt, which co-sponsored the WHA resolution along with 15 other countries. Egypt: a ‘missing piece’ in the global NCD response Professor Khaled Abdel-Gaffar, Minister of Health, Egypt. The rapid rise in metabolic liver disorders represents the “next great public health challenge,” said Khaled Abdel Ghaffar, Egyptian Minister of Health, at the EASL event. Egypt was one of the first WHO member states to sound the global health alarm around SLD after having grappled years earlier with some of the world’s highest rates of hepatitis C infection – and related viral liver disease burden. What followed was a landmark national campaign to eradicate hep C. But Egypt also suffers from a growing prevalence of diabetes, obesity, and cardiovascular disease – all risk factors for SLD. So early on, it became a champion for recognition of the liver disease as an important NCD. “Building on our experience and recognizing this urgent global need, Egypt has taken another decisive step in leadership,” said Ghaffar. “We proudly sponsored the landmark WHO resolution steatotic liver disease, a missing piece in the global non-communicable disease response.” Growing SLD burden closely linked to diabetes and obesity Comparison of a healthy liver and one with SLD, commonly known as fatty liver disease. SLD affects an estimated 1.7 billion adults globally – who suffer from the metabolic-associated liver dysfunction. In WHO’s European region alone, some 800,000 people die of advanced liver disease each year – costing some $64 billion annually. Its former name, fatty liver disease, remains in fact, an apt description of the condition insofar as SLD is linked to an excess build up of fat in the liver. This may be due to heavy alcohol use or to metabolic dysfunctions related to other NCDs, such as: obesity, insulin resistance, hyperglycemia or pre-diabetes, high cholesterol levels, and hypertension. With few early warning signs, the disease can quickly progress to severe inflammation, cirrhosis, and liver cancer. Globally, the number of new cases of liver cancers have already increased by 50% in the past decade–and are expected to double by 2050. Experts point to SLD as now a major cause of the current surge of liver cancer–which is in turn fueled by rising obesity and diabetes rates. The resolution highlights the shared NCD risk factors characteristic to the development of SLDs, including unhealthy diets, air pollution, smoking, physical inactivity and consequent obesity, as well as harmful alcohol use. It officially incorporates SLD into the broader umbrella of NCDs addressed by the global health agency. Member states are urged to integrate SLD into their noncommunicable disease strategies through strengthened prevention, early detection, primary care services, and public awareness. And the resolution calls on WHO to support research, surveillance, and equitable access to diagnostics and treatment. “For the first time, liver disease receives formal recognition within the global noncommunicable disease agenda,” EASL said in a statement, hailing the resolution as a “turning point” for liver health worldwide. Now, said Shawcross, it’s up to member states to implement the WHA resolution, moving beyond “siloed approaches” to NCDs to include liver health. Along with that, countries, supported by WHO, need to ensure more intentional tracking of liver health metrics: “What is not measured is ignored,” she said. Shift in populations at risk for liver diseases and liver cancers From left: Moderator Nicola Bedlington; Dr Pedro Gullón, Spanish Ministry of Health; Alison Cox, NCD Alliance; Prof Faisal Abaalkhail, Saudi Society for the Study of Liver Disease and Transplantation; Dr Kerri Elgar, OECD. In the Gulf region, like in Egypt, there has also been a shift in demand for liver transplants from people with viral hepatitis infections to individuals with SLDs, said Faisal Abaalkhail, president of the Saudi Society for the Study of Liver Disease and Transplantation, at the EASL event. He attributes this to the “huge rise” in obesity and diabetes. His patients are now also younger, something he calls “alarming.” Abaalkhail’s research and medical practice have pioneered liver transplants in the Gulf region. And in the past ten years, more than a third of the patients requiring liver transplants suffered from some form of SLD, he said. Early screening and detection are critical, he said, along with standardization of care for all SLD patients. “We often catch SLD too late,” said Abaalkhai. “We diagnose at the end with complications like cancer and liver failure.” But a greater emphasis on prevention is also important, he added. That includes better access to GLP-1 treatments for people who are obese or living with type 2 diabetes. With new treatments available, the region now needs to work on prioritizing exactly who can access them–including SLD patients through public health systems and insurance plans. See related story: WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug Need to integrate SLD into national NCD strategies The WHA resolution “highlights the growing recognition of the need to address metabolic conditions in a more integrated way,” said Dr Tedros Adhanom Ghebreyesus. “Metabolic conditions are becoming an increasingly important challenge globally,” he said in a message to the EASL event. “The rising prevalence of obesity, diabetes, cardiovascular and steatotic liver diseases, are driven by shared risk factors and determinants.” Added Henri Kluge, WHO European Regional Director: “Globally we are seeing the consequences of a rapidly changing metabolic disease landscape. Obesity, diabetes, cardiovascular diseases, chronic kidney disease and steatotic liver disease are on the rise – interconnected conditions shaped not only by biology but also by the unhealthy environments. “ Spain: tackling SLD as a ‘socially transmitted disease’ In Spain, steatotic liver disease historically has been under-recognized, although awareness is growing, noted Spain’s Director General of Public Health Pedro Gullón. In 2024, the Spanish Association for Liver Studies adopted the Spanish National Liver Health Plan, recognizing SLD as a public health threat and calling for better alignment with non-communicable disease (NCD) frameworks. Gullón is hopeful that the political momentum generated by the WHA resolution will prompt other member states to follow Spain’s example. Meanwhile, Spain is also passing new laws that should help prevent SLD. That includes stricter limits on alcohol consumption and displays in public places, particularly those frequented by children, like sports complexes, stadiums, and schools. Alcohol misuse is a leading cause of cirrhosis and liver cancer. “These are socially transmitted diseases,” Gullón observed. “When we do these kinds of policies, it’s not just for children, we are doing them for the whole population.” Closing the gap between WHA promises and delivery Despite this, civil society groups and watchdogs have been quick to point to the yawning gap between global health promises made by member states at the annual World Health Assembly and delivery on the ground in countries. Many of the same member states that co-sponsored the liver health resolution have struggled to control the overall rise of other NCDs, said Allison Cox, policy director of the NCD Alliance, at the EASL event. The NCD Alliance, which is tracking these disparities in its reporting, has argued for several measures to close this gap: protect policymakers from conflicts of interest, strengthen health care systems, and address the harmful commercial determinants of health. The UN General Assembly’s adoption in December 2025 of the High Level Declaration on NCDs and Mental Health is “encouraging”, Cox said. Formal adoption of the declaration from a meeting in September was delayed for several months by opposition from the United States. But, “targets don’t save lives. Implementation does,” Cox said. ‘Turning off the tap’- preventing a silent epidemic New OECD report cites a potential GDP gain of nearly 4% if leading NCD risks were eliminated, averting millions of deaths every year. The economic co-benefits of addressing liver health are also apparent, argued Kerri Elgar, senior global health advisor at the OECD. An OECD report published in April concluded that eliminating avoidable NCDs due to risks across six factors (air pollution, harmful alcohol use, unhealthy diet, obesity physical activity and smoking) would not only save millions of lives but also boost average GDP by 3.9%, on average across the 27 countries of the European Union, as well as reducing health expenditures by 40% between 2026-2050. Elgar noted the “synergies” between chronic diseases and the co-benefits with cardiovascular disease, diabetes, and other non-communicable diseases. Changing the environments that we live in is crucial to promoting prevention at these synergies, added Cox. “There’s the old public health adage that we need governments to move away from mopping the floor and turn off the tap,” she said in reference to tackling the upstream risks driving NCDs, including liver disease. “If they want to stop mopping that floor, that really means tackling commercial determinants of health,” Cox said. “Some of the most cost-effective ways of coping with noncommunicable diseases–like liver disease – is to tackle the modifiable risk factors: smoking, alcohol, unhealthy diets and air pollution, and the dominance of ultra-processed food.” Image Credits: Kenny Eliason/ Unsplash, Commons , EASL, Quora, Sophia Samantaroy/HPW , OECD, April 2026. How to Treat the Disinformation ‘Virus’ Undermining Health and Democracy 28/05/2026 Kerry Cullinan Disinformation proliferated during COVID-19 and became more organised and intent on undermining trust in science and institutions. The recent hantavirus outbreak triggered a wave of disinformation along similar lines to the COVID-19 pandemic: the virus was “fake”, “deliberately engineered”, and could be “cured” by Ivermectin. In the past week, furious community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital in the Democratic Republic of Congo (DRC) three times, motivated by misinformation and mistrust. While anti-science propaganda is not new, AI and social media platforms have enabled deliberate distortions (disinformation) and inaccurate information (misinformation) to proliferate instantly and at enormous scale. Health is one of the casualties of rising geopolitical division – from Russian bot farms spreading fake COVID-19 information to undermine Western governments, to Western leaders using slurs like “China virus” instead of coronavirus. Parts of the ‘Big Wellness’ sector are also actively undermining science-based medicines to drive people to their products. Threat to democracy Céline Jurgensen, France’s Ambassador to the UN in Geneva. Céline Jurgensen, France’s Ambassador to Geneva, describes the rapid spread of false information and disinformation as a challenge for both “health security and democratic resilience”. Post-COVID, there is “increased mistrust towards health authorities, questioning of vaccine policies, and weakening trust in science”, she said. “This phenomenon has become broader. It’s become ideological, and it’s sometimes institutionalised in its orchestration,” Jurgensen told a roundtable on dis- and misinformation at last week’s World Health Assembly. Many of the narratives are “anti-system, anti-science” aimed at “creating broad mistrust in public authorities, international organisations including the UN, and researchers”. Helen Clark, chair of the vaccine platform Gavi and former Prime Minister of New Zealand, calls mis- and disinformation “an existential threat to public health”, representing a “crisis of trust”. “We see less trust in institutions, science, and vaccines. We see polarisation. We see the disinformation actors who exploit and profit from what they do. We see people using AI chatbots and search engines for health information.” Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer, described misinformation and disinformation as “anti-system, is anti-multilateralism, and anti democratic”, requiring solutions that address all these areas, including health. “The advances that we’ve made in sexual reproductive health and rights, maternal health, and child health have been driven primarily by evidence, and there is a concentrated effort to erode that evidence,” said Akinfaderin. “We have seen concentrated strategic efforts by anti-rights and anti-gender actors, particularly, to undermine scientific evidence and to create distrust in the system.” Influencing health outcomes Robert Mardini, Director General of Geneva University Hospitals. “Misinformation and disinformation are no longer sitting at the periphery of our challenges, but very much at the core, front and centre of the daily humanitarian response, but also clinical realities,” said Robert Mardini, Director General of Geneva University Hospitals and former head of the International Committee of the Red Cross. “They influence how patients interpret their symptoms, whether they are they seek care, how they adhere to treatments, and how communities respond to public health recommendations.” Examples of disinformation are easy to find. Last year, Pakistan introduced the HPV vaccine, which protects against cervical cancer. “Gavi research found that vaccine-related search of videos on Facebook in Urdu returned vaccine misinformation in 27% of the top-ranked videos, compared to 17% in support of the vaccine,” said Clark. During COVID-19, a fake letter falsely attributed to a senior physician at the Geneva University Hospital claimed that the vaccine caused infertility, said Mardini. “In another case, national public health guidance was distorted and went global, falsely suggesting that Switzerland had declared vaccines dangerous,” he added. Akinfaderin has been confronted with claims in Nigeria and Uganda that contraceptives are linked to infertility and cervical cancer, some even spread by women’s rights organisations. Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer. Brazil’s Secretary of Health, Dr Mariângela Simão, said her country was still dealing with vaccine hesitancy from when Jair Bolsonaro was the president and “was a denialist right of both the pandemic and of vaccines”. Prof Alexandra Calmy, who heads the HIV unit at the University of Geneva Hospital, said that the day after US President Donald Trump suggested a link between paracetamol and autism in pregnant women, patients at her clinic refused pain relief. A trust problem “Misinformation is not primarily a communication challenge. It is a trust problem,” said Mardini. “Trust must be treated as a strategic public asset,” said Dr Sopon Iamsirithaworn, Deputy Secretary of Thailand’s Ministry of Public Health. “People don’t follow health measures just because they receive information. What really matters is whether they trust the system and believe in the message they hear.” But, he added, in Thailand “trust doesn’t come from the centre alone. It is built at the community level with trusted people on the ground, including our village health volunteers who live in the community”. Health authorities and governments are no match for the speed and scale at which chatbots and generative AI can generate fake information. But there are tools to dismantle some fake news. Regulating tech platforms Clark stresses increased access to “quality health information”, a “much better understanding of the real impact of mis- and disinformation on health incomes”, and holding tech platforms accountable for their role in purveying misinformation. “What might regulators insist that they do to clean up their act and stop being the purveyors of the kind of mis and disinformation that is going to cost people’s lives and health?” she asks. France has a national strategy for combating disinformation in health, which could inspire some other countries, says Jergensen. The European Union’s Digital Services Act seeks to “strengthen the responsibility of digital platforms” to clamp down on the spread of illicit or misleading content, she points out. “We also need to strengthen regional and international ways that we share information, and to cooperate in early warnings.” Simão notes that, in Brazil’s National Health System in Brazil, there is a legal requirement f to have civil society participation. Iamsirithaworn stresses speedy responses to misinformation and strengthening governments’ “social listening capacity” to understand what people are hearing and thinking. Akinfaderin calls for strengthened capacity, particularly in the global south, to challenge the notion that being anti-science is akin to decolonisation. ‘Together for Science and Health’ WHO Chief Scientist Sylvie Briand WHO Chief Scientist Sylvie Briand stresses the need to “listen, connect, and communicate”. Her division aims to launch a movement called ‘Together for Science and Health’ to address mis- and disinformation. Mardini acknowledges that misinformation spreads “faster than our collective ability to counter it” “We will not solve disinformation by correcting falsehood faster. We must build systemic resilience by strengthening scientific literacy, investing in transparency, reinforcing links between science and communities, and working through trusted international networks. He also calls for “supporting healthcare workers as trusted communicators”, as they are “the most credible interface between science and society, but they need time, training and institutional backing to play this role”. “Ultimately, the question is not only how we fight misinformation and disinformation, but whether we create environments where it cannot easily take root and spread.” Image Credits: EU vs DiSiNFO. Africa CDC Chief Condemns Ebola Travel Restrictions and Broken Aid Promises 28/05/2026 Kerry Cullinan Africa CDC Director General Dr Jean Kaseya International Ebola-related travel restrictions imposed on people from the Democratic Republic of Congo (DRC), Uganda and South Sudan – which has yet to record a single case – are “unacceptable” will have a detrimental effect on the economies of affected countries, said Dr Jean Kaseya, head of the Africa Centres for Disease Control and Prevention on Thursday. The US was the first to ban travellers from the three countries, with Canada, the Bahamas, Jordan and Bahrain following, but Kaseya said 15 countries have now imposed some form of travel restrictions. “We cannot stop this outbreak with travel restrictions that Western countries have started to impose on African countries. It even a shame to see a country like South Sudan, with zero suspected cases and zero deaths, under travel restriction. The treatment that Western countries are applying to Africa… it’s not acceptable,” said Kaseya, speaking from the DRC’s capital, Kinshasa. During the last large Ebola outbreak in 2018, West Africa lost $53 billion or 12% of their GDP, said Kaseya. By Wednesday, there were 1077 suspected cases in the DRC and 246 deaths, including “three very young doctors” in Bunia in Ituri province, the epicentre of the outbreak, Kaseya reported. However, more cases are expected as given that the outbreak is centred in a remote and conflict-ridden, Two countries are affected but 11 countries on their borders are at risk, and Africa CDC is also working with these countries to strengthen their surveillance capacity. “Tomorrow, I will be in Burundi meeting the president and senior officials to see how the country is getting ready if the cases that we have in South Kivu [in neighbouring DRC] are detected also in Burundi. This is why we are really running –l et me correct myself, we are not running, we are flying – to make sure that we can stop this outbreak very quickly.” ‘Mistrust of Western countries’ Kaseya said that he had visited Bunia in the last few days where he encountered “mistrust of Western countries” by people in the area. “The question they are asking me is: ‘DG, why after 19 years of this [disease], we still don’t have a vaccine, we still don’t have medicine? A local leader was telling me: ‘If this outbreak was in Europe or in the US, a vaccine and medicines will already be available’,” Kaseya told the media briefing. Kaseya also condemned countries that had pledged financial support for the outbreak effort only to renege a few days later, saying that he would name them within a week if they did not make good on their promises. The DRC will contribute $50 million to the effort, but the need is in the region of $319 million. “On Monday (25 May), we ended the day with a pledge of $498.8 million almost $500 million Since then the figure is going down. Now, as I’m talking to you, the figure is around $290 million We cannot afford to stop this outbreak without resources. We cannot afford to stop this outbreak just with political declaration from some countries,” he said. Africa CDC has developed a list of priority tasks for all affected sectors, making a particular appeal to communities to trust and protect health workers. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. Kaseya said that churches and local radio stations were being mobilised to assist to reach affected communities and provide them with accurate information about the disease and their risks. The US State Department announced on Thursday that it has “mobilized more than $112 million in bilateral foreign assistance for the Ebola response in less than two weeks”, with an additional $80 million in bilateral assistance to key partners finalised this week. “These new resources will enable implementing partners to scale up the following critical response activities: PPE procurement and delivery, border screening and surveillance, contact tracing, and diagnostics supplies,” the US State Department said. WHO Calls for ‘Immediate Ceasefire’ to Enable Ebola Response 28/05/2026 Kerry Cullinan Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients. The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”. The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday. The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals. “Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned. The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths. However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. “We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.” Travel restrictions Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home. This week, Canada also closed its borders to the same three countries. However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”. The ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”. It has also deployed an ECDC expert to the Africa CDC to support its response. Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult. Race for vaccines, treatment Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak. There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period. Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately. Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies. The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS. But this has to be injected, making it less suitable for remote areas such as Ituri. Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US. The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients. Image Credits: AP, Africa CDC. Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
How to Treat the Disinformation ‘Virus’ Undermining Health and Democracy 28/05/2026 Kerry Cullinan Disinformation proliferated during COVID-19 and became more organised and intent on undermining trust in science and institutions. The recent hantavirus outbreak triggered a wave of disinformation along similar lines to the COVID-19 pandemic: the virus was “fake”, “deliberately engineered”, and could be “cured” by Ivermectin. In the past week, furious community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital in the Democratic Republic of Congo (DRC) three times, motivated by misinformation and mistrust. While anti-science propaganda is not new, AI and social media platforms have enabled deliberate distortions (disinformation) and inaccurate information (misinformation) to proliferate instantly and at enormous scale. Health is one of the casualties of rising geopolitical division – from Russian bot farms spreading fake COVID-19 information to undermine Western governments, to Western leaders using slurs like “China virus” instead of coronavirus. Parts of the ‘Big Wellness’ sector are also actively undermining science-based medicines to drive people to their products. Threat to democracy Céline Jurgensen, France’s Ambassador to the UN in Geneva. Céline Jurgensen, France’s Ambassador to Geneva, describes the rapid spread of false information and disinformation as a challenge for both “health security and democratic resilience”. Post-COVID, there is “increased mistrust towards health authorities, questioning of vaccine policies, and weakening trust in science”, she said. “This phenomenon has become broader. It’s become ideological, and it’s sometimes institutionalised in its orchestration,” Jurgensen told a roundtable on dis- and misinformation at last week’s World Health Assembly. Many of the narratives are “anti-system, anti-science” aimed at “creating broad mistrust in public authorities, international organisations including the UN, and researchers”. Helen Clark, chair of the vaccine platform Gavi and former Prime Minister of New Zealand, calls mis- and disinformation “an existential threat to public health”, representing a “crisis of trust”. “We see less trust in institutions, science, and vaccines. We see polarisation. We see the disinformation actors who exploit and profit from what they do. We see people using AI chatbots and search engines for health information.” Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer, described misinformation and disinformation as “anti-system, is anti-multilateralism, and anti democratic”, requiring solutions that address all these areas, including health. “The advances that we’ve made in sexual reproductive health and rights, maternal health, and child health have been driven primarily by evidence, and there is a concentrated effort to erode that evidence,” said Akinfaderin. “We have seen concentrated strategic efforts by anti-rights and anti-gender actors, particularly, to undermine scientific evidence and to create distrust in the system.” Influencing health outcomes Robert Mardini, Director General of Geneva University Hospitals. “Misinformation and disinformation are no longer sitting at the periphery of our challenges, but very much at the core, front and centre of the daily humanitarian response, but also clinical realities,” said Robert Mardini, Director General of Geneva University Hospitals and former head of the International Committee of the Red Cross. “They influence how patients interpret their symptoms, whether they are they seek care, how they adhere to treatments, and how communities respond to public health recommendations.” Examples of disinformation are easy to find. Last year, Pakistan introduced the HPV vaccine, which protects against cervical cancer. “Gavi research found that vaccine-related search of videos on Facebook in Urdu returned vaccine misinformation in 27% of the top-ranked videos, compared to 17% in support of the vaccine,” said Clark. During COVID-19, a fake letter falsely attributed to a senior physician at the Geneva University Hospital claimed that the vaccine caused infertility, said Mardini. “In another case, national public health guidance was distorted and went global, falsely suggesting that Switzerland had declared vaccines dangerous,” he added. Akinfaderin has been confronted with claims in Nigeria and Uganda that contraceptives are linked to infertility and cervical cancer, some even spread by women’s rights organisations. Kemi Akinfaderin, Fòs Feminista’s chief global advocacy officer. Brazil’s Secretary of Health, Dr Mariângela Simão, said her country was still dealing with vaccine hesitancy from when Jair Bolsonaro was the president and “was a denialist right of both the pandemic and of vaccines”. Prof Alexandra Calmy, who heads the HIV unit at the University of Geneva Hospital, said that the day after US President Donald Trump suggested a link between paracetamol and autism in pregnant women, patients at her clinic refused pain relief. A trust problem “Misinformation is not primarily a communication challenge. It is a trust problem,” said Mardini. “Trust must be treated as a strategic public asset,” said Dr Sopon Iamsirithaworn, Deputy Secretary of Thailand’s Ministry of Public Health. “People don’t follow health measures just because they receive information. What really matters is whether they trust the system and believe in the message they hear.” But, he added, in Thailand “trust doesn’t come from the centre alone. It is built at the community level with trusted people on the ground, including our village health volunteers who live in the community”. Health authorities and governments are no match for the speed and scale at which chatbots and generative AI can generate fake information. But there are tools to dismantle some fake news. Regulating tech platforms Clark stresses increased access to “quality health information”, a “much better understanding of the real impact of mis- and disinformation on health incomes”, and holding tech platforms accountable for their role in purveying misinformation. “What might regulators insist that they do to clean up their act and stop being the purveyors of the kind of mis and disinformation that is going to cost people’s lives and health?” she asks. France has a national strategy for combating disinformation in health, which could inspire some other countries, says Jergensen. The European Union’s Digital Services Act seeks to “strengthen the responsibility of digital platforms” to clamp down on the spread of illicit or misleading content, she points out. “We also need to strengthen regional and international ways that we share information, and to cooperate in early warnings.” Simão notes that, in Brazil’s National Health System in Brazil, there is a legal requirement f to have civil society participation. Iamsirithaworn stresses speedy responses to misinformation and strengthening governments’ “social listening capacity” to understand what people are hearing and thinking. Akinfaderin calls for strengthened capacity, particularly in the global south, to challenge the notion that being anti-science is akin to decolonisation. ‘Together for Science and Health’ WHO Chief Scientist Sylvie Briand WHO Chief Scientist Sylvie Briand stresses the need to “listen, connect, and communicate”. Her division aims to launch a movement called ‘Together for Science and Health’ to address mis- and disinformation. Mardini acknowledges that misinformation spreads “faster than our collective ability to counter it” “We will not solve disinformation by correcting falsehood faster. We must build systemic resilience by strengthening scientific literacy, investing in transparency, reinforcing links between science and communities, and working through trusted international networks. He also calls for “supporting healthcare workers as trusted communicators”, as they are “the most credible interface between science and society, but they need time, training and institutional backing to play this role”. “Ultimately, the question is not only how we fight misinformation and disinformation, but whether we create environments where it cannot easily take root and spread.” Image Credits: EU vs DiSiNFO. Africa CDC Chief Condemns Ebola Travel Restrictions and Broken Aid Promises 28/05/2026 Kerry Cullinan Africa CDC Director General Dr Jean Kaseya International Ebola-related travel restrictions imposed on people from the Democratic Republic of Congo (DRC), Uganda and South Sudan – which has yet to record a single case – are “unacceptable” will have a detrimental effect on the economies of affected countries, said Dr Jean Kaseya, head of the Africa Centres for Disease Control and Prevention on Thursday. The US was the first to ban travellers from the three countries, with Canada, the Bahamas, Jordan and Bahrain following, but Kaseya said 15 countries have now imposed some form of travel restrictions. “We cannot stop this outbreak with travel restrictions that Western countries have started to impose on African countries. It even a shame to see a country like South Sudan, with zero suspected cases and zero deaths, under travel restriction. The treatment that Western countries are applying to Africa… it’s not acceptable,” said Kaseya, speaking from the DRC’s capital, Kinshasa. During the last large Ebola outbreak in 2018, West Africa lost $53 billion or 12% of their GDP, said Kaseya. By Wednesday, there were 1077 suspected cases in the DRC and 246 deaths, including “three very young doctors” in Bunia in Ituri province, the epicentre of the outbreak, Kaseya reported. However, more cases are expected as given that the outbreak is centred in a remote and conflict-ridden, Two countries are affected but 11 countries on their borders are at risk, and Africa CDC is also working with these countries to strengthen their surveillance capacity. “Tomorrow, I will be in Burundi meeting the president and senior officials to see how the country is getting ready if the cases that we have in South Kivu [in neighbouring DRC] are detected also in Burundi. This is why we are really running –l et me correct myself, we are not running, we are flying – to make sure that we can stop this outbreak very quickly.” ‘Mistrust of Western countries’ Kaseya said that he had visited Bunia in the last few days where he encountered “mistrust of Western countries” by people in the area. “The question they are asking me is: ‘DG, why after 19 years of this [disease], we still don’t have a vaccine, we still don’t have medicine? A local leader was telling me: ‘If this outbreak was in Europe or in the US, a vaccine and medicines will already be available’,” Kaseya told the media briefing. Kaseya also condemned countries that had pledged financial support for the outbreak effort only to renege a few days later, saying that he would name them within a week if they did not make good on their promises. The DRC will contribute $50 million to the effort, but the need is in the region of $319 million. “On Monday (25 May), we ended the day with a pledge of $498.8 million almost $500 million Since then the figure is going down. Now, as I’m talking to you, the figure is around $290 million We cannot afford to stop this outbreak without resources. We cannot afford to stop this outbreak just with political declaration from some countries,” he said. Africa CDC has developed a list of priority tasks for all affected sectors, making a particular appeal to communities to trust and protect health workers. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. Kaseya said that churches and local radio stations were being mobilised to assist to reach affected communities and provide them with accurate information about the disease and their risks. The US State Department announced on Thursday that it has “mobilized more than $112 million in bilateral foreign assistance for the Ebola response in less than two weeks”, with an additional $80 million in bilateral assistance to key partners finalised this week. “These new resources will enable implementing partners to scale up the following critical response activities: PPE procurement and delivery, border screening and surveillance, contact tracing, and diagnostics supplies,” the US State Department said. WHO Calls for ‘Immediate Ceasefire’ to Enable Ebola Response 28/05/2026 Kerry Cullinan Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients. The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”. The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday. The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals. “Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned. The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths. However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. “We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.” Travel restrictions Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home. This week, Canada also closed its borders to the same three countries. However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”. The ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”. It has also deployed an ECDC expert to the Africa CDC to support its response. Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult. Race for vaccines, treatment Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak. There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period. Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately. Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies. The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS. But this has to be injected, making it less suitable for remote areas such as Ituri. Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US. The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients. Image Credits: AP, Africa CDC. Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
Africa CDC Chief Condemns Ebola Travel Restrictions and Broken Aid Promises 28/05/2026 Kerry Cullinan Africa CDC Director General Dr Jean Kaseya International Ebola-related travel restrictions imposed on people from the Democratic Republic of Congo (DRC), Uganda and South Sudan – which has yet to record a single case – are “unacceptable” will have a detrimental effect on the economies of affected countries, said Dr Jean Kaseya, head of the Africa Centres for Disease Control and Prevention on Thursday. The US was the first to ban travellers from the three countries, with Canada, the Bahamas, Jordan and Bahrain following, but Kaseya said 15 countries have now imposed some form of travel restrictions. “We cannot stop this outbreak with travel restrictions that Western countries have started to impose on African countries. It even a shame to see a country like South Sudan, with zero suspected cases and zero deaths, under travel restriction. The treatment that Western countries are applying to Africa… it’s not acceptable,” said Kaseya, speaking from the DRC’s capital, Kinshasa. During the last large Ebola outbreak in 2018, West Africa lost $53 billion or 12% of their GDP, said Kaseya. By Wednesday, there were 1077 suspected cases in the DRC and 246 deaths, including “three very young doctors” in Bunia in Ituri province, the epicentre of the outbreak, Kaseya reported. However, more cases are expected as given that the outbreak is centred in a remote and conflict-ridden, Two countries are affected but 11 countries on their borders are at risk, and Africa CDC is also working with these countries to strengthen their surveillance capacity. “Tomorrow, I will be in Burundi meeting the president and senior officials to see how the country is getting ready if the cases that we have in South Kivu [in neighbouring DRC] are detected also in Burundi. This is why we are really running –l et me correct myself, we are not running, we are flying – to make sure that we can stop this outbreak very quickly.” ‘Mistrust of Western countries’ Kaseya said that he had visited Bunia in the last few days where he encountered “mistrust of Western countries” by people in the area. “The question they are asking me is: ‘DG, why after 19 years of this [disease], we still don’t have a vaccine, we still don’t have medicine? A local leader was telling me: ‘If this outbreak was in Europe or in the US, a vaccine and medicines will already be available’,” Kaseya told the media briefing. Kaseya also condemned countries that had pledged financial support for the outbreak effort only to renege a few days later, saying that he would name them within a week if they did not make good on their promises. The DRC will contribute $50 million to the effort, but the need is in the region of $319 million. “On Monday (25 May), we ended the day with a pledge of $498.8 million almost $500 million Since then the figure is going down. Now, as I’m talking to you, the figure is around $290 million We cannot afford to stop this outbreak without resources. We cannot afford to stop this outbreak just with political declaration from some countries,” he said. Africa CDC has developed a list of priority tasks for all affected sectors, making a particular appeal to communities to trust and protect health workers. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. Kaseya said that churches and local radio stations were being mobilised to assist to reach affected communities and provide them with accurate information about the disease and their risks. The US State Department announced on Thursday that it has “mobilized more than $112 million in bilateral foreign assistance for the Ebola response in less than two weeks”, with an additional $80 million in bilateral assistance to key partners finalised this week. “These new resources will enable implementing partners to scale up the following critical response activities: PPE procurement and delivery, border screening and surveillance, contact tracing, and diagnostics supplies,” the US State Department said. WHO Calls for ‘Immediate Ceasefire’ to Enable Ebola Response 28/05/2026 Kerry Cullinan Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients. The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”. The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday. The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals. “Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned. The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths. However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. “We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.” Travel restrictions Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home. This week, Canada also closed its borders to the same three countries. However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”. The ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”. It has also deployed an ECDC expert to the Africa CDC to support its response. Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult. Race for vaccines, treatment Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak. There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period. Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately. Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies. The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS. But this has to be injected, making it less suitable for remote areas such as Ituri. Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US. The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients. Image Credits: AP, Africa CDC. Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
WHO Calls for ‘Immediate Ceasefire’ to Enable Ebola Response 28/05/2026 Kerry Cullinan Members of the Red Cross bury people who have died of Ebola in Rwampara in the DRC, guarded by military personnel after attacks on a treatment facility for Ebola patients. The World Health Organization’s (WHO) Director General has called for an immediate ceasefire in the eastern DRC to enable officials to address the outbreak of a particularly deadly strain of Ebola, warning that stopping transmission “depends entirely on humanitarian access”. The DRC’s Ituri province, the heart of the Ebola Bundibugyo virus outbreak, is facing “a catastrophic collision of disease and conflict”, Tedros warned on Wednesday. The DRC army and the M23 rebel group are locked in combat, largely focused on control over the region’s minerals. “Ongoing clashes are driving mass displacement, pushing exposed contacts into overcrowded camps and severing critical containment corridors. Frontline workers are risking everything, while attacks on health facilities make tracking cases and their contacts nearly impossible,” Tedros warned. The Africa Centres for Disease Control and Prevention has warned that the outbreak could infect up to 7,500 people. On 23 May, it reported almost 1000 suspected cases and over 100 deaths. However, it is difficult to confirm cases as samples from the outbreak zone must travel 1,700 kilometres – often on rudimentary roads – to reach the Institut National de Recherche Biomédicale in Kinshasa, the only facility in the country with the capacity to test for Bundibugyo. The conflict has also made it difficult for health officials to provide residents with information about the outbreak, for which there are no approved vaccines or treatments, and a death rate of up to 50%. Community members have attacked and torched tents housing Ebola patients at Mongbwalu General Referral Hospital three times in the past week, demanding the bodies of their relatives for burials – unaware that their bodies remain infectious after death. In the latest attack, a seriously ill patient died while trying to escape the burning tent and 18 others fled. “We cannot build community trust or isolate the sick while bombs are falling,” said Tedros. “We urge all warring parties to agree to an immediate ceasefire to contain this outbreak. To allow us safe and sustained access for medical teams.” Travel restrictions Last week, the United States (US) closed its borders to citizens from the DRC, Uganda and South Sudan, and this week it emerged that US citizens exposed to the virus in these African countries will be quarantined in Kenya rather than flown home. This week, Canada also closed its borders to the same three countries. However, a spokesperson for the European Centre for Disease Prevention and Control (ECDC) said on Wednesday that “the risk of infection to the general population in Europe remains very low”, but stressed that it is “crucial to reduce risk by identifying travellers who are symptomatic”. The ECDC is assisting the European Union and European Economic Area (EU/EEA) to “rapidly detect and isolate anyone infected who is arriving from the regions affected and carry out all necessary control measures”. It has also deployed an ECDC expert to the Africa CDC to support its response. Meanwhile, Uganda – which has confirmed 17 cases – has closed its border with the DRC. Within the DRC, flights to Bunia in Ituri have been suspended, both containing the outbreak and making humanitarian efforts more difficult. Race for vaccines, treatment Meanwhile, scientists are racing to adapt current Ebola research, which is focused on the more widespread Zaire strain, to address the Bundibugyo outbreak. There are plans to extend a Phase 3 trial of the oral antiviral treatments, remdesivir (Obeldesivir) and Molnupiravir, to include the highest-risk contacts of people infected with Bundibugyo, testing whether they can stop or minimise infection within the 21-day infection period. Dr Marie Jaspard, a French infectious disease researcher who heads the Ebola Post-Exposure Prophylaxis (EboPEP) research group, told a WHO scientific webinar earlier this week that scientists are redesigning the protocol as fast as they can, but that suitable high-risk contacts will be able to receive treatment immediately. Obeldesivir is an oral form of remdesivir, which is suitable for remote settings, although its safety in children and pregnant women has not yet been established. Molnupiravir, which proved effective against COVID‑19 experience, has shown some efficacy against Ebola in animal studies. The most advanced treatment candidate for Bundibugyo is MBP134, “a cocktail of two broad-spectrum monoclonal antibodies, capable of neutralising several viral species of Orthoebolavirus”, which has already been tested on primates, according to the French scientific research agency, ANRS. But this has to be injected, making it less suitable for remote areas such as Ituri. Meanwhile, DRC Health Minister Roger Kamba said that his country has requested access to a monoclonal antibody tested against all three Ebola strains – Zaire, Sudan, and Bundibugyo – that has been developed in the US. The DRC has officially requested access to this experimental treatment to launch a clinical trial for confirmed patients. Image Credits: AP, Africa CDC. Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
Global Temperatures Head For Record Highs in Next Five Years 28/05/2026 Disha Shetty Temperature projections from the World Meteorological Organization (WMO) warn that temperatures will rise further in the next five years. Global average temperatures are likely to reach record levels in the coming five years, the latest report from the World Meteorological Organization (WMO) warns, released amid news that the UK recorded its hottest day in May ever earlier this week. Temperatures in the Arctic region are expected to continue to be higher than the global mean, according to the report produced by the United Kingdom’s Met Office and released on Thursday. A record-breaking heatwave is sweeping across Europe, causing misery and deaths in some European countries. On Wednesday, the temperature at Heathrow Airport in London reached 35°C, the hottest day in May recorded in the UK. In some parts of France and in Spain temperatures were higher by as much as 10°C compared to normal. The WMO’s report suggests that such brutal summers will become the norm in the near future. The annual global mean near-surface temperatures during 2026–2030 are projected to range between 1.3°C and 1.9°C above the 1850-1900 average. “There is an El Niño predicted for the end of 2026, which increases the chances of the following year, 2027, being the next record-breaking year,” said Dr Leon Hermanson, the report’s lead author. There is an 86% chance that one of the years between 2026 and 2030 will surpass 2024 as the warmest year on record, according to the update. Paris Agreement target in danger The Paris Agreement target of 1.5°C is likely to be breached more often in the coming years. In 2015, global leaders agreed to try to limit global warming to 1.5°C above the pre-industrial era. The target was seen as being an example of low ambition by several low-lying countries and climate advocates. However, the world briefly breached this target in 2024 when the global average surface temperature was about 1.55 °C. The WMO report now finds that there is a 91% chance that the global mean near-surface temperature will temporarily exceed 1.5°C above the 1850-1900 between 2026 and 2030. It is also likely (75% chance) that the 2026-2030 five-year mean will exceed 1.5°C above the 1850-1900 average. For now, the 2°C mark seems to be safe and some time away. The WMO report said that it is considered exceptionally unlikely (less than 1%) that any single year will exceed 2°C above the 1850-1900 average in the next five years. With every half-degree temperature rise, the sea levels rise and put communities living in low-lying areas in danger. Arctic warming at record pace The Arctic region has been especially affected by climate change. The Arctic region is fast warming at a record pace. Arctic temperatures over the next five extended northern hemisphere winters (November-March) are predicted to be 2.8°C above average temperatures for 1991-2020. This is more than three and half times that of global mean temperature anomaly over the same period. Projections of Arctic sea-ice for March 2026-2035 suggest that there will be further reductions in sea-ice concentration in the Barents Sea, Bering Sea, and Sea of Okhotsk. The rainfall and snowfall patterns are also changing. While some areas are projected to get wetter, others are projected to get drier. In the tropics and in high latitudes, the precipitation is expected to increase compared to the 1991-2020 reference period. Precipitation is expected to decrease in the subtropics, particularly in the southern hemisphere, where a warmer climate is expected. For May-September 2026-2030, the report suggests higher precipitation in the Sahel, northern Europe, Alaska and Siberia. But Amazon is likely to be drier during this period which will also make it prone to forest fires. A guide for policymakers Small developing island states are highly vulnerable to the effects of climate change and rely on universal diplomatic processes to ensure they hold equal weight to major global powers. The 1.5°C and 2.0°C levels specified in the Paris Agreement refer to long-term warming sustained over an extended period, and not just one year. Typically, this period is at least two decades long. Individual years with annual global mean temperatures exceeding these levels do not mean that the long-term temperature goals of the Paris Agreement are out of reach. These reports are meant to guide policymakers as they formulate policies to reduce global carbon emissions. Around 13 different institutions contributed data to this report, increasing the reliability of the results. Image Credits: WMO, Unspash/Mika Baumeister, Melissa Bradley, Unsplash/Ernests Vaga. ‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
‘Failure was Never an Option’: South Africa’s mRNA ‘Hub’ Awarded Good Manufacturing Practice Certification 27/05/2026 Kerry Cullinan Afrigen CEO Prof Petro Terblanche. Afrigen Biologics, the South African facility that developed an mRNA vaccine from scratch during COVID-19, has become the first African facility to be certified to manufacture investigational biological products for Phase I and II clinical trials. The facility celebrated receiving its Good Manufacturing Practice (GMP) certification for its mRNA facility in Cape Town from the South African Health Products Regulatory Authority (SAHPRA) on Wednesday. This means that Afrigen now meets internationally recognised pharmaceutical manufacturing standards. “Failure was never an option,” said Afrigen CEO Professor Petro Terblanche, while paying tribute to her team, the World Health Organization (WHO), Medicines Patent Pool (MPP) and several key donors. Almost four years ago – on 21 June 2021 – Afrigen was selected as the “mRNA hub” by the WHO and MPP – along with BioVac and the South African Medicines Control Council. Afrigen had the “enormous task to develop an mRNA platform, to industrialise it and to transfer technology to 15 partners on four continents in low-middle-income countries representing four billion people”, she added. “We are ready to support clinical trial material production, advance technology transfer and contribute meaningfully to vaccine and biologics development and manufacturing.” Afrigen’s 15 partners – including Bangladesh, Brazil, Egypt, India, Nigeria, Ukraine, Serba and Vietnam – are using the knowledge acquired from the hub to develop mRNA products to address a wide range of challenges from cancer to dengue to foot-and-mouth disease in animals. Huge challenge of sustainability Charles Gore, head of the Medicines Patent Pool. MPP head Charles Gore described the developments over the past four years as “mindboggling”, as the programme moved “from concept to regulated manufacturing capacity and a growing global network”. “The idea that, in Africa, we would have this kind of progress and a cutting-edge technology six years ago, before COVID-19, would have been unthinkable,” said Gore. “What has developed here [has been] transferred out across LMICs to make the world a better and safer place.” However, Gore said that the next phase of the mRNA Technology Transfer Programme is to ensure that it is “really sustainable, because there is no point having the capacity if you then walk away and leave it to stagnate”. This means that Afrigen and its partners will need to make – and sell – high quality products to governments and companies. As previously reported by Health Policy Watch, the key challenge facing all mRNA hub partners is to ensure that governments procure their vaccines and medicines – although the new start-ups’ products are likely to be more expensive than the giant pharma firms that have been in the business for years and are already supplying large global markets. Milestone for Africa Dr Claudia Nannei, WHO’s team lead in product development and manufacturing WHO Director General Dr Tedros Adhanom Ghebreyesus, told the gathering via a video message that the GMP certification is “an important milestone not only for South Africa and the African continent, but also for global health”. “Afrigen now serves as a quality-assured strategic platform for regional manufacturing, contributing to secure supply, pandemic preparedness and Africa’s health sovereignty. “ Like Gore, Tedros stressed that the next phase of the programme “must focus on sustainability, strengthening product pipelines, partnerships and long-term capabilities”. Tedros also thanked the governments of South Africa, Belgium, Canada, France, Germany, and the European Commission for supporting Afrigen. Dr Claudia Nannei, WHO’s team lead in product development and manufacturing, described the GMP certification as not simply a technical or regulatory achievement. “It demonstrates that advanced quality assurance mRNA manufacturing capacity can be developed from scratch on the African continent, as long as it’s grounded on scientific excellence.” Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
Cervical Cancer Elimination Off-Track: Commonwealth Leaders Deploy New Strategies 27/05/2026 Felix Sassmannshausen Commonwealth leaders, global health experts, and diplomats gather at the inaugural Health Coordination Forum in Geneva to accelerate cervical cancer elimination. The Commonwealth’s new strategic framework accelerates the elimination of cervical cancer, a highly preventable disease that claims hundreds of thousands of lives yearly. However, shifting global funding and major prevention gaps threaten to derail progress, forcing states to double down on shared digital resources, regional cooperation, and community engagement. Inside the wood-panelled executive boardroom at the World Health Organization (WHO) headquarters in Geneva, delegates gathered ahead of the 79th World Health Assembly to discuss strategies on cervical cancer elimination in the Commonwealth, a global association of 56 countries that spans both advanced economies and low- and middle-income countries. Miriam Mutebi highlights critical global mortality rates. The atmosphere of the inaugural Commonwealth Health Coordination Forum was charged with a mixture of diplomatic ambition and the sobering reality of continued systemic failures. “Every three minutes somewhere in the world a woman is dying from cervical cancer,” said Professor Miriam Mutebi, an oncologist and chair of the Commonwealth International Task Force for Cervical Cancer Elimination. The disease is almost entirely preventable, yet it remains a leading cause of mortality among women worldwide, predominantly in low- and middle-income countries. The human papillomavirus (HPV) drives the vast majority of these fatalities, killing approximately 348,000 women annually. The Commonwealth bears a disproportionate cervical cancer burden relative to its share of global population. Low- and middle-income countries bear the highest burden The Commonwealth bears a disproportionate share of this burden, as shown in a newly published report by the Commonwealth Secretariat, developed in partnership with Roche Diagnostics. Its member states account for 40% of global incidence and 43% of mortality, despite representing only 30% of the world’s population of around 2.7 billion. While most high-income countries are currently on a trajectory to meet the WHO 2030 targets – demanding 90% vaccination, 70% screening, and 90% treatment coverage – and eliminate cervical cancer by 2050, most low- and middle-income nations lag far behind. At current rates of progress, these countries will only achieve elimination in 2120. Furthermore, without decisive action, projections suggest that new cases in the Commonwealth could rise by 55% and deaths by 62% by the year 2030. Jennifer Namgyal stresses the need for systems-level policy implementation. Facing immense challenges, achieving cervical cancer elimination demands massive logistical and financial efforts. This requires embedding cancer care into primary health systems, integrating HPV vaccination into routine immunisations, and linking screening to existing maternal services, so women do not have to navigate separate systems. “The challenge is not at all a lack of evidence. It is the absence of a sustained systems-level implementation,” said Jennifer Namgyal, Acting Senior Director of the Social Development, Youth and Gender Directorate at the Commonwealth Secretariat, in an interview with Health Policy Watch. Regional successes in fighting cervical cancer Although single-dose HPV vaccines drive regional successes, cervical cancer elimination remains off track across many Commonwealth countries. The newly released Commonwealth report outlines how low- and middle-income countries successfully leverage political will to scale up national cervical cancer elimination programmes. The compendium features 12 country case studies detailing strategic innovations across HPV vaccination, screening, and treatment. “Rwanda and Nigeria really show how strong political commitment to scaling national cervical cancer programmes can work,” said Namgyal. After transitioning to systematic HPV DNA testing in 2020, Rwanda implemented community-based self-sampling and a custom electronic medical record system to track patient data, manage clinic referrals, and automate follow-up reminders. By 2022, the country achieved 93% vaccination coverage among girls aged 9 to 14. Similarly, Nigeria launched a historic single-dose vaccination campaign, immunising approximately 17 million girls since October 2023 and increasing national coverage from under 10% to over 30%. To reach vulnerable, out-of-school populations, the government strategically distributes these vaccines through markets, religious houses, and mobile clinics. Other member states offer equally compelling blueprints, such as Zambia’s decentralised screening approach and Belize’s sustained domestic financing. Shortfalls, ODA cuts and lack of data Severe data gaps and underfunding threaten the target ten-point-five billion dollar global cervical cancer elimination strategy. Despite these localised successes, key challenges emerge around funding shortfalls and current ODA cuts across the globe, affecting last-mile delivery of vaccines and screenings by community health workers. As economic growth remains slow or even decreases, countries will face further escalating fiscal shortfalls, forcing them to shrink overall health budgets. “It is evident to us that there is severe pressure on ODA on multilateral funding, full stop,” explained Namgyal. To keep elimination efforts on track across 78 low- and lower-middle-income countries (inside and outside the Commonwealth), the WHO estimates that stakeholders must invest $10.5 billion by 2030. The majority of these investments (59%) are required for vaccination programmes, while the rest (41%) is needed for cervical cancer screening and management. However, pinpointing the funding gap remains difficult as publicly available data exists for only 27 of the 56 Commonwealth countries, and most of that data pre-dates 2020. What little evidence is available shows that funding is largely inadequate, with some countries dedicating less than 1% of their total health budget to cancer control. Confronting complex epidemiological threats HPV genotypes covered by current vaccines and percentage contribution in invasive cervical cancer. The shifting global landscape requires rapid adaptation to address overlapping epidemiological threats, particularly in regions with high HIV prevalence. Women living with HIV are six times more likely to develop cervical cancer compared to the general population, with Sub-Saharan Africa accounting for 85% of women living with both. Furthermore, the HPV-35 strain has a disproportionately higher prevalence in sub-Saharan Africa, yet it remains untargeted by existing vaccine formulations. This lack of coverage underscores the urgent need to accelerate research to create an updated, polyvalent vaccine, as the genotype accounts for a significant proportion of invasive cervical carcinoma in populations with high HIV prevalence. To prepare for these advancements, the board of the vaccine alliance Gavi approved the inclusion of improved vaccines in its portfolio in December last year, ensuring they can be made available to countries as soon as they are licensed. When asked about integrating the HPV-35 strain into future vaccines, Namgyal noted that the Commonwealth relies on specialised health organisations for clinical guidance. “We understand that best practice is established through WHO recommendations and then country-specific epidemiology then informs the rollout in those contexts,” she said. Sharing resources across vast borders From left to right: Miriam Mutebi (Commonwealth International Cervical Cancer Taskforce), Sofiat Akinola (Roche Diagnostics), Janneth Mghamba (Commonwealth Secretariat), Jennifer Namgyal (Commonwealth Secretariat), Leslie Ramsammy (Chair, CHCF). Until then, robust screening programmes and rapid treatment options remain the primary defence against these emerging strains. The Commonwealth’s strategy focusses heavily on transitioning from traditional Pap smears to DNA testing to detect these risks earlier. The Commonwealth also leverages high-level “South-South” diplomatic strategies and shared resources across the 56 member states. Rather than building isolated infrastructure, countries are leaning into collaborative networks to bypass human resource shortages and financial constraints. This strategic approach directly responds to the Lancet Oncology Commission roadmap for cancer control, which provides a framework for member states to tackle the rising incidence of the disease. Acting senior director Namgyal emphasised that the priority is translating evidence into country-led action, embedding care within primary health systems, and integrating HPV vaccination into routine immunisations. Ambassador Leslie Ramsammy of Guyana further detailed this collaborative approach during the session, stressing the necessity of leveraging shared clinical capabilities. To overcome diagnostic bottlenecks without adequate domestic specialists, Guyana invested in a digital pathology laboratory. Through this digital infrastructure, specialists in India and New York now read pathology images created in Guyana, the former health minister said. Community engagement versus misinformation Educational toolkits and self-sampling guides combat cultural stigma by empowering women with direct health information. While diplomatic strategies and shared pathology labs address structural deficits, implementation on the ground requires navigating complex cultural barriers. Global health guidelines recommend engaging communities directly to overcome gender and social hurdles that traditionally hinder vaccination efforts. The combination of direct community engagement and grassroots mobilisation via youth-focused approaches by NGOs like Girl Effect, alongside advocacy groups such as Zambia’s Teal Sisters and the Belize Cancer Society, creates a comprehensive ecosystem for disease control. Global health leaders now cite Malawi as a champion model after a recent grassroots campaign targeting schoolgirls successfully extended HPV vaccine coverage above 90%. Another successful strategy involves First Ladies and spouses of Heads of Government across the Commonwealth, whose advocacy proves transformative in breaking silences and reducing misconceptions that prevent women from seeking care. To further lift the stigma, experts recommend gender-neutral vaccination programmes that also include boys. “Breaking down stigma, making it more accessible and more ordinary to speak about is a very helpful part of that,” said acting senior director Namgyal. However, this can only succeed if health systems possess the capacity and funding to actually deliver the vaccines and screenings. Non-binding approach, fiscal constraints With multilateral funding currently constrained, major hurdles remain because the Commonwealth approach is non-binding. Therefore, the path forward requires a relentless focus on translating high-level commitments into sustainable, community-level solutions. Guyana’s Ambassador Leslie Ramsammy called for cross-border cooperation. “This first forum does not end this afternoon – this first forum will continue working until we have that action plan,” said Ambassador Leslie Ramsammy, former Minister of Health for Guyana and permanent representative to the United Nations in Geneva, committed to developing a concrete action plan. “Economic status and geography should not bring death to our doors.” However, without ramping up resources, these efforts may struggle to achieve the WHO’s elimination targets. Until then, women will continue to suffer and die from a disease with established, cost-effective prevention and treatment methods. See also: Available Cervical Cancer Vaccines Fail to Cover the HPV 35 Genotype Common in Africa Image Credits: WHO/Genna Print , CHCF via Flickr, Felix Sassmannshausen/HPW, CHCF via Flickr, Murahwa et al, Reviews in Medical Virology, 33 March 2026. Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts
Snakebite – Long Ignored, Recently Recognized as Neglected Disease 26/05/2026 Disha Shetty Professor Mohammad Abul Faiz (Bangladesh) accepting the Dr Lee Jong-wook Memorial Prize for Public Health in May 2026. Snake bites are neglected even amongst neglected tropical diseases (NTDs), said Bangladesh’s Professor Mohammad Abul Faiz, who was awarded the prestigious Dr Lee Jong-wook Memorial Prize at an event on the sidelines of last week’s World Health Assembly (WHA). The prize is for individuals, institutions, and governmental or nongovernmental organisations whose contributions to public health have gone beyond the call of duty. Faiz, who was honoured for his work on NTDs, including snakebites, is an authority on infectious and tropical diseases, including malaria and snakebite envenomings – a process in which the snakebite introduces venom into a person’s body. A medical doctor, he has worked in the public health sector in Bangladesh for 32 years, including as that country’s Director General of Health Services and as Dean of Medicine at the University of Dhaka. He led Bangladesh’s first nationwide study on snakebite envenoming, the first in Asia, and is the author of both the Bangladesh Snakebite Guideline and the WHO Global Snakebite Guideline. He also co-chaired the WHO Snakebite Envenoming Working Group, was a member of the WHO group on malaria treatment guidelines, and has collaborated with major international initiatives on neglected diseases and malaria control. While semi-retired, Faiz is still active in public life as the president of the Toxicology Society of Bangladesh and the founder of the Dev Care Foundation, a non-profit that works on health promotion and disease prevention with marginalised communities. In his acceptance speech, Faiz pointed out that snake bites are the only non-communicable disease listed in the WHO’s list of 21 neglected tropical diseases, “So it does not fit either in the communicable diseases, where they deal with NTDs, nor the non-communicable diseases, which are overburdened with classical non-communicable diseases: hypertension, diabetes, stroke, coronary artery disease etctera,” Faiz said. He said that community engagement had been essential in his work on snake bites and malaria, particularly to counter bureaucracy. “The trickling [of information] from the centre, down to the community is a long process… so also is the funding process. So engaging the community upfront is essential,” he said. Shining a spotlight on snakebites Millions are bitten by snakes every year, and struggle to access care. An estimated 5.4 million people worldwide are bitten by snakes each year and around 1.8 to 2.7 million cases of envenomings, according to the WHO. Most snake bites happen in Africa, Asia and Latin America. They can be fatal, cause paralysis and lead to amputations. While treatments do exist, only a handful of countries produce the antivenoms. Cost and access are both barriers to effective treatment. Faiz’s career of over two decades was also spent working on diseases like malaria that affect vulnerable populations in low-resource settings. “His work on snake bite envenoming reminds us of a reality that is too often invisible: the burden of neglected tropical diseases that affect millions of people, particularly in the most vulnerable regions of our planet,” said Robert Mardini, Director of Geneva University Hospitals, at the award ceremony. Snake bite envenoming was recognised in 2017 by the WHO as a high-priority neglected tropical disease, said Mardini. “This recognition did not happen by chance. It is the result of years of research, advocacy, and field engagement. “Fundamental progress in global health happens only when science, field experience and institutions work in collaboration work hand in hand,” Mardini added. The existing antivenoms, “may not properly reflect the geographical variation that occurs in the venoms of some widespread species,” according to the WHO. Climate change is worsening inequities in health Sania Nishtar, CEO of the global vaccine alliance Gavi. The prize-giving ceremony, co-hosted by the WHO and the Geneva Health Forum, also served as a gathering of global health leaders to discuss ideas. “There’s an inextricable relationship between animal health, human health, and environmental health. In our line of work, we see it playing out very, very often now. So diseases are appearing in areas where they were not recognisable at one point in time,” said Sania Nishtar, CEO of the global vaccine alliance, Gavi. She added that while there are funding challenges, many countries have also stepped up their domestic health funding, particularly in Africa, which is a positive sign. The prize is awarded in honour of Dr Lee Jong-wook, the sixth Director-General at the World Health Organization (WHO), and died at the age of 61 in 2006. “He believed in equity, he believed in solidarity, and the fundamental right to health for all,” said Saia Ma’u Piukala, regional director of the WHO Western Pacific Region. “His work [in] expanding access to essential medicines, strengthening preparedness, advancing universal health coverage and investing in health workers and communities continues to shape WHO priorities today,” he added. Image Credits: WHO, WHO. Posts navigation Older postsNewer posts